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1A brief summary of the work to be presented in the thesis entitled
"DISCOVERING THE NEW HETEROCYCLES OF THERAPEUTIC
INTEREST" has been described as under.
[A] STUDIES ON QUINOLINE DERIVATIVES
The group of the compounds containing quinoline moiety are a
prominent structural feature in a variety of natural products like echipsine,
quinine and cinchonine as well as in other compounds of medicinal interest
and have attracted attention for their biological activities viz. CNS depressant,
hypnotic, sedatives, antimalarial, antiinflammatory, fungicidal, analgesic,
antitumor, antiulcer, anticonvulsant, antidiabetic, antiarrhythmic, antitumor,
antagonist and antidepressant. Taking in view of the applicability of
heterocyclic compounds, we have undertaken the synthesis of heterocycles
like pyrazolines, isoxazoles, imidazolines, cyanopyridines, cyanopyridones,
pyr imid inones ,  a ry l id ines ,  barb i tones  and n i t r i l es  bear ing  2 ,7-
dichloroquinoline-3-carboxaldehyde nucleus. Our efforts are focused on
the introduction of chemical diversity in the molecular frame work in order
to synthesise pharmacologically interesting compounds of widely different
composition.
PART - I  : STUDIES ON PYRAZOLINES
Pyrazolines have been found to possess bactericidal, fungicidal,
antiviral and other pharmacological properties like tuberculostatic, local
anaesthetic, CNS depressant, anticonvulsant, antiinflammatory, analgesic,
antipyretic, antidepressant and antifertile activities. Hence it was thought
worthwhile to synthesise pyrazoline derivatives for better drug potential,
which have been described in following sections.
SECTION - I : Synthesis, characterisation and therapeutic
evaluation of 1-Aryl-3-(2',7'-dichloroquinolin-3'-
yl)-2-propene-1-ones
The chalcones of type (I) have been synthesised by the condensation
of 2,7-dichloroquinoline-3-carboxaldehyde with various aromatic ketones.
SECTION - II : Synthesis, characterisation and therapeutic
evaluat ion of  1-Acety l -3-ar y l -5 - (2 ' ,7 ' -
dichloroquinolin-3'-yl)-pyrazolines
Pyrazolines of type (II) have been prepared by the condensation of
the chalcones of type (I) with hydrazine hydrate and acetic acid.
SECTION - III : Synthesis, characterisation and therapeutic
evaluation of 1H-3-Aryl-5-(2',7'-dichloroquinolin-
3'-yl)-pyrazolines
2
NCl Cl
R
O
Type (I) R = Aryl
Type (II) R = Aryl
NCl Cl
N
N
CH3O
R
Pyrazoline derivatives of type (III) have been prepared by the
condensation of the chalcones of type (I) with hydrazine hydrate.
PART - II  : STUDIES ON CYANOPYRIDINES
Like other heterocyclic compounds, pyridine with different functional
groups exhibit wide range of applications in the field of pharmaceutical and
agriculture. Some cyanopyridine derivatives have been found to be
associated with pharmacological activities such as antifungal, antidiabetic,
anticholestemic and antihypertensive. They have been also used for dyes
for cotton and polyester fabrics. On the basis of these results, we have
synthesised new derivatives which have been described as under.
SECTION - I : Synthesis and therapeutic evaluation of 2-
Amino-3-cyano-4-(2',7'-dichloroquinolin-3'-yl)-6-
aryl pyridines
2-Amino-3-cyanopyridine derivatives of type (IV) have been
synthesised by the condensation of chalcones of type (I) with ammonium
acetate and malononitrile.
NCl Cl
N
N
H
R
Type (III) R = Aryl
NCl Cl
N
R
NH2
N
Type (IV) R = Aryl
3
PART - III  : STUDIES ON CYANOPYRIDONES
Recent ly subst i tuted cyanopyridone derivat ives have drawn
considerable attention due to their good pharmacological activities like
anticonvulsant, antibacterial,  anti infective and antimalarial.  These
observations prompted us to combine this nucleus into well known
pharmaceutical properties of  2,7-dichloroquinoline-3-carboxaldehyde
moiety, so as to enhance the overall activities of resulting moiety, which
have been described as under.
SECTION - I : Synthesis and therapeutic evaluation of 1,2-
Dihydro-3-cyano-4-(2',7'-dichloroquinolin-3'-yl)-
6-aryl-2-pyridones
Cyanopyridone derivatives of type (V) have been synthesised by the
condensation of chalcones of type (I) with ammonium acetate and ethyl
cyano acetate.
PART - IV  : STUDIES ON BARBITONES
The group of compounds containing the barbituric acid ring system
have a prominent feature in medicinal chemistry and possess biological
activities such as hypnotic, herbicidal and anticonvulsant. In view of these
valid observations it was contemplated to synthesise some new barbitones
possessing higher biological activity which have been described has under.
Type (V) R = Aryl
4
NCl Cl
NH
R
O
N
SECTION - I : Synthesis and therapeutic evaluation of [1-Aryl-
3-(2',7'-dichloroquinolin-3'-yl)-2-propenylidine]-
5-barbituric acids
Barbitone derivatives of type (VI) have been synthesised by the
condensation of chalcones with barbituric acid.
PART - V  : STUDIES ON ISOXAZOLES
Isoxazole derivatives represent one of the modest class of compounds
possessing wide range of therapeutic activities such as antidepressant, skeleton
muscle relaxant, analgesic and sedative. Keeping this in view, it was
considered of interest to synthesise some novel isoxazole derivatives as under.
SECTION - I : Synthesis and therapeutic evaluation of 3-Aryl-
5-(2',7'-dichloroquinolin-3'-yl)-isoxazoles
Isoxazole derivatives of type (VII) have been synthesised by the
condensation of the chalcones of type (I) with hydroxylamine hydrochloride.
5
NCl Cl
R
NH
N
H
O
O
O
Type (VI) R = Aryl
NCl Cl
N
O
R
Type (VII) R = Aryl
PART - VI  : STUDIES ON IMIDAZOLINES
5-Oxo imidazoline derivatives have been reported to be active as
antiinflammatory, potent CNS depressant, sedatives, hypnotics, anticancer
agent and mono amino oxidase (MAO) inhibitor. Thus significant biological
properties associated with imidazolinone derivatives have aroused
cons iderab le  in te res t  to  des ign the  compounds  in  which 2 ,7-
dichloroquinoline-3-carboxaldehyde nucleus is incorporated with a view
to getting compounds with better drug potential, which have been described
as under.
SECTION - I : Synthesis and therapeutic evaluation of 1N-Aryl-
2-phenyl-4-(2',7'-dichloroquinolin-3'-methinyl)-
5-imidazolinones
The compounds of type (VIII) have been prepared by the condensation
of different amines with azalactones of 2,7-dichloroquinolin-3-carboxaldehyde,
which in turn were prepared by well known Erlenmeyer azalactone synthesis.
PART - VII : STUDIES ON 5-ARYLIDENE-4-THIAZOLIDINONES
The interesting biological activities of a novel heterocycle like
thiazolidinone have stimulated considerable research work in recent years
leading to the synthetic utility of the derivatives of this ring system. In order
to achieve compounds having better drug potential, we have combine 2,7-
d ich loroquino l ine-3-carboxa ldehyde wi th  d i f fe rent  subs t i tu ted
thiazolidinones. The pharmacological profile of the synthesised compounds
have been studied and described as under.
6
NCl Cl
N
N
O
R
Type (VIII) R = Aryl
SECTION - I : Synthesis and therapeutic evaluation of 2-
Arylimino-3N-aryl-5-(2',7'-dichloroquinolin-3'-
methinyl)-4-thiazolidinones
The compounds of type (IX) have been prepared by the condensation
of 2,7-dichloroquinoline-3-carboxaldehyde with different 4-thiazolidinone
derivatives.
PART - VIII  : STUDIES ON THIAZOLIDINOPYRIMIDINONES
Thiazolidinopyrimidinone derivatives represent one of the most active
class of compounds possessing a wide spectrum of biological activity such
as significant invitro activity against unrelated DNA and RNA viruses,
antimalarial ,  diuret ic,  antibacterial  and spermicidal.  Led by these
considerations, some new thiazolidinopyrimidinone derivatives were
prepared, which have been described as under.
SECTION - I : Synthesis and therapeutic evaluation of 7-(2',7'-
Dichloroquinolin-3 ' -yl) -2-arylimino-3-aryl-
thiazolidino[4,5 -d]-pyrimidine-4,5,6,7-tetrahydro-
5-ones
7
N ClCl
N
H
NH
S
N
N RR
O
Type (X) R = Aryl
NCl Cl
N
SO
N RR
Type (IX) R = Aryl
The compounds of type (X) have been prepared by the reaction of
2,7-dichloroquinoline-3-carboxaldehyde with urea, conc HCl and different
4-thiazolidinones.
PART - IX  : STUDIES ON α-ARYLAMINONITRILES
The growing potent literature of recent years demonstrates that the
nitrile derivatives are used as better herbicidal, antifungal and antibacterial
agents. Prompted by above facts some newer nitriles have been synthesised
which have been described as under.
SECTION - I : Synthesis and therapeutic evaluation of α-Aryl-
amino-α-2,7-dichloroquinolin-3-yl-acetonitriles.
The compounds of  type (XI)  have been synthesised by the
condensation of 2,7-dichloroquinolin-3-carboxaldehyde with potassium
cyanide and various aromatic amines.
The constitution of the newly synthesised products have been
characterised using elemental analysis, Infrared and 1H nuclear magnetic
resonance spectroscopy and further supported by mass spectrometry. Purity
of all the compounds has been checked by thin layer chromatography.
8
NCl Cl
CN
NH
R
Type (XI) R = Aryl
In vitro study on multiple biological activites:
(i) All the compounds have been evaluated for their antibacterial activity
towards Gram positive and Gram nagative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of
40 µg/ml. The biological activity of the synthesised compounds have
been compared with standard drug.
(ii) Selected compounds have been evaluated for their invitro biological
assay like antitubercular activity towards a strain of Mycobacterium
tuberculosis H 37 Rv at a cocentration of 6.25 µg/ml using Rifampin
as a s tandard drug, which have been tested by Tuberculosis
Antimicrobial Acquisition Co-ordinating Facility (TAACF), Alabama
U.S.A.
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DISCOVERING THE
NEW HETEROCYCLES OF
THERAPEUTIC INTEREST
INTRODUCTION
The current interest in the creation of large, searchable libraries of organic
compounds has captured the imagination of organic chemists and the drug
discovery community. Effor ts in numerous laboratories focused on the
in t roduct ion of  chemica l  d ivers i ty  have been recent ly  rev iewed and
pharmacologically interesting compounds have been identified from libraries of
widely different composition.
Today our world increasingly is conceived of as being molecular. An ever
widening range of phenomena are described logically in terms of molecular
properties and molecular interactions. The majority of known molecules are
heterocyclic and heterocycles dominate the fields of biochemistry, medicinal
chemistry, dye stuffs, photographic science and are of increasing importance in
many others, including polymers, adhesive and molecular engineering.
Heterocycles, containing nitrogen are most abundant in nature than those
containing oxygen or sulfur. Considerable diversy in the ring system is possible.
The number of atoms in the heterocyclic ring can range from three to many.
The smallest ring possible is three membered, i.e. ethylene oxide, but very large
rings are possible in the case of crown ethers.
Most of the alkaloids, which are nitrogenous bases occurring in plants and
many antibiotics including penicillin and streptomycin also contain heterocyclic
r ing system. Many natural  pigments such as indigo, heamoglobin and
anthocyanin are heterocycles. Most of the sugars, their derivatives including
vitamin C for instance, exist largely in the form of five membered or six membered
ring containing nitrogen. Life saving drugs, poisons and medicines (both natural
and synthetic) such as sulfathiazole, pyrethrin, ratennone, strychnine, reserprine,
the ergot alkaloids caeffine, cocaine, barbiturates etc. are heterocyclic.
10
The process of drug design is extensively driven by instincts, infution and
experience of pharmaceutical research scientists. It is often instructive to attempt
to  "capture" these experiences by analyzing the historical research that is
successful drug design projects of past. From this analysis, the interference is
drawn to play an important role in shapping our own current and future projects.
Towards this region, we would like to analyse the structure of a large number of
drugs, the ultimate product of a successful drug design effort. Our goal for this
is to deconvolute this information in order to apply it to design new drugs.
A drug is a substance having abnormal effect on certain body functions,
eg. Strichnine stimulates the action of heart and Aspirin still its action. Since
both of them effects abnormally, both are known as  drugs. Chemical sciences
contributed extensively new discoveries leading to useful drugs since 1930. The
modern concept of drug discovery started in 1933 by Gerhand Dogmak with
his finding of "Protonsil Red" a compound responsible for the antibacterial
activity. The advent of sulfonamides drew attention to the different activity of
various chemicals for bacterial and human cells, this important factor prompted
the Flory and Chain in 1939 to investigate penicillin which was discovered ten
years earlier by Alexander Fleming. The spectecular chemotherapeutical
properties of penicillin and its dramatic war time development for the treatment
of wounds made penicillin, a most commonly used inexpensive drug.
The "Golden Period" of new drug discovery was 1930 to 1960, a very
large number of important drugs had been introduced during that period, such
as:
NAME OF DRUGS YEAR USAGES
Sulfa drugs 1933 First antibacterial drug
Penicillin 1940 Antibiotic
Chloroquine 1945 Antimalarial
Methyl Dopa 1950 Antihypertensive
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Chlorthiazide 1957 Diuretic
Adrenergic beta blockers 1958 Coronary Vasodilatory
Semi synthetic penicillin 1960 Antibacterial
Trimethoprim 1965 Antimicrobial
Disodium chromoglycoate 1970 Antiallergic
AIMS AND OBJECTIVES
In the pharmaceutical field, these have always been and will continue to
be a need for new and novel chemical inhibitors of biological function. Our
efforts are focused on the introduction of chemical diversity in the molecular
frame work in order to synthesizing pharmacologically interesting compounds
of widely different composition.
During the course of research work, looking to the application of
heterocyclic compounds, several entities of heterocyclic compounds have been
designed, generated and characterised using spectral studies. The details are as
under.
(i) To generate several derivatives like chalcones, pyrazolines, isoxazoles,
cyanopyridones, pyrimidinones, imidazolones bearing quinoline ring
system.
(ii) To synthesise arylidenes, cyanopyridines, barbitones, nitriles bearing
quinoline moiety.
(iii) To characterise these product for structure elucidation using spectroscopic
techniques like IR, PMR and mass spectral studies.
(iv) To check the purity of all compounds using thin layer chromatography.
(v) To evaluate these new products for better drug potential against different
strains of bacteria and fungi.
Taking in view of the applicabil i ty of heterocyclic compounds, the
construction of new heterocycles of therapeutic importance, bearing quinoline
nucleus have been investigated in following parts.
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STUDIES ON
QUINOLINE
DERIVATIVES
INTRODUCTION
The quinoline contains a phenyl ring fused to pyridine ring, and also known
as benzopyridine (I).
Quinoline is a very important heterocyclic compound as it is featured in a
variety of natural products, as well as in other compounds of medicinal interest
and have attracted attention for their biological activities. The chemistry of
quinoline and its derivatives, has been the centre of attention for long time. R.
H. Manske1 and F. W. Bergstrom2 has done excellent work on quinoline and its
derivatives.
SYNTHETIC ASPECT
Different methods for the synthesis of quinoline derivatives are as follows:
(1) J. A. Moore et al. have synthesised 6-hydroxyquinoline by the oxidation of
hydroxyquinolines by means of ferricyanide3.
(2) T. Kametani et al.4 have synthesised quinoline derivatives by deoxygenation
with the help of triphenylphosphite.
(3) o-Nitrocinnamaldehyde was reduced to quinoline by potassiumtetra
carbonylhydrido ferrate was demonstrated by C. K. Bradsher and T. G.
Wallis.5
(4) M. Lancaster and D. J. H. Smith6 have prepared tetrahydroquinoline
derivatives of type (II).
N
(I)
Quinoline... 13
(5) Meth-Cohn and co-workers7 have shown that treatment of acetanilides
with the Vilsmeir Haack reagent with POCl3 as solvent al lows the
preparation of quinoline derivative of type (III).
MECHANISM
In the first step hydroxy group is replaced by chlorine, which is possible by
lone pair of electron of halogen atom. In the second step Vilsmeir - Haack reagent
attacks on nucleophile and forms quaternarry ammonium ion as an intermediate.
This intermediate on treatment by POCl3 leads to the quinoline molecule.
THERAPEUTIC IMPORTANCE
Fol lowing are  some quino l ine  der iva t ives  repor ted to  possess
pharmacological activity :
Quinoline...
N
COOH
Cl
Me
(II)
N Cl
CHO
(III)
N
H
CH3
O N
CH3
OH
POCl3
N
CH3
Cl
Vilsmeir-Haack reagent
(DMF    POCl3)+N Cl
N+
CH3
CH3
N
CH3CH3
N Cl
CHO
Cyclization
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Quinoline and its annelated substrates occupy a unique place in the field
of medicinal chemistry due to their wide spectrum of therapeutic activities which
can be listed as under.
1. Antiinflammatory8-12
2. Antidepressant13
3. Antiallergic14,15
4. Antihypertensive16
5. Antiviral17,18
6. Antitumor19,20
7. Antiulcer21
8. Anticonvulsant22
Quinoline...
N
NH
CH3
(CH2)3 N
C2H5
C2H5
Cl
Amidoquine
(Antimalarial)
Chloroquine
(Antimalarial)
N
N
H
OH
CF3
CF3
NH
O
OCH2
OH
NH
CH3 CH3
CH3
Cartelal
(β-Adrenergic blocker)
Mefloquine
(Antimalarial)
Norfloxacin
(Antibacterial)
N
C2H5
O
COOHF
N
NH
N
NH OH
CH2N(C2H5)2. 2 HCl. 2 H2O
Cl
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9. Analgesic23,24
10. Antimicrobial25-27
11. Antiarrythmic28
12. Antitubercular29,30
13. Antithrombotic31
14. Antiplatlet32-34
15. Antimalarial35
16. Antithyroid36
O. Teruo et al.37 have prepared some new quinoline derivatives (IV) and
documented them as bradykinin antagonists.
Desai P. K. and co-workers38 reported some new quinoline derivatives as
antitubercular agent. Balasubramanian C. and co-workers39 synthesised some
novel benzopyranopyranoquinoline derivatives (V) and tested their antibacterial
activity.
Quinoline...
O
O N
O
R
R'
CH3H OH
(V)
N
O
CH3
ClCl
N
N
H
N
O
O
CH3
CO2C2H5
(IV)
16
K. Seiichiro et al.40 synthesised quinoline sulfide derivatives as selective
antibacterial  agents. D. H. Joan and co-workers41 prepared quinoline
sulfonamides and described them as tumor necrosis factor (TNF) inhibitors. C.
T. Lee et al.42 synthesised some new imidazolinyl quinolines (VI) and
documented them as alpha-2-adrenoceptor agonists.
Klein E. S. et al.43 prepared some new quinoline derivatives and reported
them as retinoid receptor antogonists. C. S. Hoon and co-workers44 reported
antitumor activity of some new 2-quinolone derivatives. Multidrug resistance
modulating activity of a new series of tetrahydroquinolines was documented by
H. Romana and co-workers.45
S. Yoshida and co-workers46 prepared some new quinolone derivatives
and reported their antiulcer activity. 4-Oxoquinoline derivatives are reported
as antibacterial agents by Sarvanan J. et al.47 Some quinolines of type-(VIII)
have been prepared by M. G. Matthias and co-workers48 and reported as
antiarterioscierotics.
Quinoline...
N
H
NH
N
R
R1
N
(VI)
N
F
F
OH
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(VII)
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Antimalarial activity of some new 4-aminoquinolines was reported by
Raynes K. J. and co-warkers.49 B. T. Richard et al.50 synthesised some new
piperazinyl methyl quinolines and documented them as antipsychotics.
Anticancer act ivi ty of 8-hydroxyquinol ines was repor ted by Shen and
co-workers.51
Quinoline derivatives of type (VIII) have been described by Xue C. B. and
co-workers52 and documented them as TNF inhibitors.
G. Qingchun et al.53 described some new fluoroquinoline derivatives and
tested their antibacterial activity. S. Sudahira and co-workers54 synthesised
some new quinol ine carboxyl ic acid derivat ives and repor ted them as
bactericidal. Wackernagel and co-workers55 studied some new quinoline
derivatives and reported them as insecticidals. M. Jigna56 synthesised some
new arylquinolinyl pyrimidinones and screened for their antibacterial activity.
Crooks S. L. et al.57 prepared some new amidoether substituted quinolines
(IX) as immune response modifiers.
Quinoline...
N
CH3
O
S
O
O
N
CH3
NH
O
OH
(VIII)
X = - (CH2)2-, -CH - CH2
CH2CH3
R1, R2, Rn = Aryl
N
N
N
NH2
X O
R1
R2
Rn
(IX)
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M. Jansen and co-workers58 repor ted some new quinolones and
documented them as antagonists. Antibacterial activity of some new quinoline-
2-one  he terocyc les  was  repor ted by  Suchetak  e t  a l .59  Use  o f
quinolinylmethylsulfonyl butyl formamides (X) in the treatment of autoimmune
disease and allergies were shown by B. D. John and co-woerkers.60
P. Uwe and co-workers61 have described some new pyrolidinyl quinolones
and reported them as antibacterial agents and food additives. Desouza N. J. et
al.62 investigated some new quinolone carboxaldehyde derivatives and reported
their effect against multidrug resistance bacteria. F. M. Grazia and co-workers63
studied some pyrazoloquinolines (XI) and documented their vasorelaxing effect.
The universal template approach to drug design foresees that quinolines
can be modified in such a way to afford better therapeutic agents, we have
designed chalcones, pyrazolines, cyanopyridines, cyanopyridones, barbitones,
isoxazoles, imidazolines arylidienes, pyrimidinones and nitriles bearing 2,7-
dichloroquinoline-3-carboxaldehyde moiety, which is described in the following
parts.
Quinoline...
(X)
N S
O
O
OCH3CH3
N
CHO
OH
N
N
H
N
N
Phenyl
(XI)
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STUDIES ON QUINOLINE DERIVATIVES
PART-I : STUDIES ON PYRAZOLINES
PART-II : STUDIES ON CYANOPYRIDINES
PART-III : STUDIES ON CYANOPYRIDONES
PART-IV : STUDIES ON BARBITONES
PART-V : STUDIES ON ISOXAZOLES
PART-VI : STUDIES ON IMIDAZOLINONES
PART-VII : STUDIES ON 5-ARYLIDENE-4-THIAZOLIDINONES
PART-VIII : STUDIES ON THIAZOLIDINOPYRIMIDINONES
PART-IX : STUDIES ON α-ARYLMINONITRILES
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PART - I
STUDIES ON
PYRAZOLINES
INTRODUCTION
Pyrazolines are known to be among those heterocycles which find their
utility in various fields of life. The significance of this moiety has increased due
to its biocompability. The chemistry of pyrazoline was reviewed by Jarboe in
1967, which have been studied extensively for their biodynamic behaviour64,
and industrial applications65.
SYNTHETIC ASPECT
Different methods are available in literatures for the preparation of 2-
pyrazolines. The popular methods are:
1. The most common procedure for the synthesis of 2-pyrazolines is the
cyclocondensation of chalcones with hydrazine hydrate66.
2. 2-Pyrazolines can be also prepared by the condensation of di-bromo
derivative of chalcone with hydrazine hydrates67.
3. 2-Pyrazolines can be constructed by the cycloaddition of diazomethane to
substituted chalcones68.
N
H
N
(I)
N
H
NR
R
R
O
R' + NH2.NH2.H2O
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4. A number of diarylidene cycloalkanones on reaction with hydrazine hydrate
produce pyrazolines69.
5. Epoxidation of chalcones  gave epoxy ketones which reacted with hydrazine
hydrate and phenyl hydrazine to give pyrazolines70.
REACTION MECHANISM
The following mechanism seems to be operable for the condensation of
chalcones with hydrazine hydrate71.
Nucleophillic attack by hydrazine at the β-carbon of the α,β-unsaturated
carbonyl system forms species (II), in which the negative charge is mainly
accommodated by the electronegative oxygen atom. Proton transfer from the
nitrogen to oxygen produces an intermediate end which simultaneously ketonises
to ketoamine (III). Another intramolecular nucleophillic attack by the primary
amino group of ketoamine on its carbonyl carbon followed by proton transfer
from nitrogen to oxygen leads  ultimately to hydroxyl amine (IV). The later with
a hydroxy group and amine group on the same carbon lose water easily to yield
the pyrazolines.
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THERAPEUTIC IMPORTANCE
From the literature survey, it was revealed that 2-pyrazoline derivatives
are better therapeutic agents.
1. Insecticidal72
2. Diuretic73
3. Fungicidal74
4. Herbicidal75
5. Hypoglycemic76
6. Antiallergic77
7. Anticonvulsant78
8. Antidiabetic79
9. Antiinflammatory80
10. Antitumor81
11. Cardiovascular82
12. Analgesic83
13. Antineoplastic84
14. Bactericidal85
15. Tranquilizing86
T. S. Katshaki et al.87 have synthesised some new (phenylcarbonyl)
pyrazoline (I) as an insecticide which at 40% concentration shows 100% mortality
of spodopeira litura  lurve after seven days.
N
N
O
NH
CF3
R (I)
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F. Manna and co-workers88 have described 1-acetyl-5-(2'-bromophenyl)-
4,5-dihydro-3-(2'-hydroxyphenyl)-1H-pyrazolines (II) and its derivatives which
acts as potent antiinflammatory, analgesic and antipyretic agents.
Fuche Rainer  et al.89 have prepared some new 1H-pyrazoline derivatives
(III) and reported them as pesticides.
Moreover Ismil et al.90 have prepared pyrazoline derivatives bearing
sulfonamide moiety and tested their antimicrobial activity. Sarhan and co-
workers91 have synthesised pyrazolines derivatives and repor ted their
antibacterial, analgesic and antiinflammatory activities. S S. Sonarc et al.92
have studied 3-(2-acetoxy-4-methoxyphenyl)-5-(substituted phenyl)-pyrazolines
(IV) for their antimicrobial activity.
NN
OH
(H3C)2-N
H3COC
R
R1
(II)
N
H
N
N N
Cl
(III)
(IV)
NN
OACH3CO
R
R1
R2
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G. N. Mishirika et al.93 have also  prepared 2-pyrazolines derivatives of
salicylic acid (V) possessing antimicrobial properties.
Further more, T.M. Stavenson et al.94 have also investigated N-substituted
pyrazoline type insecticides. Tanka Katsohori95 have patented pyrazoline
derivatives as herbicides.
CONTRIBUTION FROM OUR LABORATORY
Jatin Upadhyay et al.96 have prepared 1-acetyl-4,5-dihydro-5-(4-hydroxy-
3-methoxyphenyl)-3-(4-phenyl-sulfonylaminophenyl)-1H-pyrazole and other
derivatives which possess antimicrobial activity. Synthesis of some novel
pyrazolines as biologically potent agents bearing quinazolone nucleus has been
reported by Oza H. et al.97 Parikh et al.98 have synthesised m,m'-bis(5-aryl-1-
phenyl)-pyrazolin-3-yl-p-phenyl-amino sulfonyl benzophenones and screened
for their antimicrobial activity. Antimicrobial activity of pyrazolines have been
documented by H. H. Parekh and co-workers.99
Shivananda M.K. and co-workers100 have prepared pyrazolines and
repor ted their antibacterial activity. B. Shivarama Holla et al.101 have
synthesised pyrazolines (VI) and reported their antibacterial activity.
(V)
NN
R
R
OH
COOH
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O
N
N
Ac
R
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(VI)
E. Palaska et al.102 have prepared 3,5-diphenyl-2-pyrazoline derivatives
and studied their antidepressant activity. S.P. Hiremath and co-workers103 have
repor ted analgesic, anti inf lammatory and antimicrobial activity of 3,5-
disubstituted pyrazolines (VII).
Thus interesting biological activities of a novel heterocycles like pyrazolines
have stimulated considerable research work in recent years leading to the
synthetic utility of the derivatives of this ring system. In our search for new
potential antimicrobial compounds, the reaction series of chalcones with
hydrazine hydrate under different conditions has been investigated and the
pharmacological profile of the compounds have been studied and described as
under.
SECTION I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
1-ARYL-3-(2',7 ' -DICHLOROQUINOLIN-3'-YL)-2-
PROPENE-1-ONES
SECTION II : SYNTHESIS AND THERAPEUTIC EVALUATION OF
1-ACETYL-3-ARYL-5-(2',7'-DICHLOROQUINOLIN-3'-
YL)-PYRAZOLINES
SECTION III : SYNTHESIS AND THERAPEUTIC EVALUATION OF
1H-3-ARYL-5-(2',7'-DICHLOROQUINOLIN-3'-YL)
PYRAZOLINES
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-3-(2',7'-
DICHLOROQUINOLIN-3'-YL)-2-PROPENE-1-ONES
During the past years, considerable evidence has been accumulated to
demonstrate the efficiency of chalcones in including variety of therapeutic
activities. To further assess the potential of such a class of compounds  as
antibacterial and antifungal agents, a series of chalcones of type (I) have been
synthesised by the condensation of 2,7-dichloroquinoline-3-carboxaldehyde with
various aromatic ketones.
The constitution of the synthesised products has been characterised using
elemental analyses, infra red and 1H nuclear magnetic resonance spectroscopy
and further supported by mass-spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in  Part-I Section-I (D). The
ant imycobacter ia l  ac t iv i ty  was  car r ied out  towards  Mycobacter ium
tuberculosis at 6.25 µg concentration using Rifampin as a standard drug.
NCl Cl
R
O
Type (I) R = Aryl
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REACTION
Type (I) R = Aryl
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NCl Cl
R
O
NCl Cl
CHO
R-COCH3
NHCOCH3
Cl
+ DMF + POCl3
IR SPECTRAL STUDY OF 1-p-TOLYL-3-(2'-7'-DICHLORO-QUINOLIN-3'-YL)-2-
PROPENE-1-ONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str. 2998 2975-2850 419
C – H def. 1471 1470-1435 "
Aromatic C– H str. 3064 3090-3030 "
C = C str. 1471 1520-1480 "
C – H def. 1014 1070-1000 420
813 835-810 "
Quinoline C = N str. 1602 1610-1590 419
moiety C = C str. 1602 1610-1590 "
C – Cl str. 725.2 750-700 "
Chalcone C = O str. 1662 1690-1665 "
Vinyl CH = CH 3064 3050-3000 "
NCl Cl
O
CH3
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PMR SPECTRAL STUDY OF 1-(p-ANISYL)-3-(2',7'-DICHLOROQUINOLIN-3'-YL)-2-
PROPENE-1-ONES
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity J. Value Inference
No. (δ ppm) of Protons in Hz
1 3.97 3H singlet - Ar-OCH3
2. 7.00-7.03 2H doublet Jih 8.81 Ar-Hi,i'
3. 7.55-7.59 1H double doublet Jfg 8.67 Ar-Hf
Jfd 1.8
4. 7.60-7.65 1H doublet JBA 15.56 =CHB
5. 7.82-7.85 1H doublet Jgf 8.64 Ar-Hg
6. 8.03-8.04 1H doublet Jdf 2.00 Ar-Hd
7. 8.06-8.09 2H doublet Jhi 8.83 Ar-Hh,h'
8. 8.13-8.19 1H doublet JAB 15.86 =CHA
9. 8.46 1H singlet - Ar-Ha
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NCl Cl
O
OCH3
d
f
g a A
B
h'
i'
h
i
1a C6H5 1658
1b 3-NH2-C6H4 1660
1c 4-NH2-C6H4 1662
1d 4-Br-C6H4 1658
1e 4-Cl-C6H4 1656
1f 2,6-(OH)2-C6H3 1660
1g 4-F-C6H4 1662
1h C4H3O 1658
1i 2-OH-C6H4 1632
1j 4-OH-C6H4 1660
1k 4-OCH3-C6H4 1658
1l 4-CH3-C6H4 1662
1m 3-NO2-C6H4 1660
1n 4-NO2-C6H4 1660
Sr.
 No. R
C=O str.
Chalcone
EXPANDED AROMATIC REGION
IR SPECTRAL DATA OF 1-ARYL-3-(2',7'-DICHLOROQUINOLIN-3'-YL)-2-PROPENE-
1-ONES
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
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ANTIMICROBIAL ACTIVITY
Method : Cup Plate
Gram positive bacteria : B. megaterium., S.aureus
Gram negative bacteria : E. coli., P. vulgaris
Fungi : Aspergillus niger
Concentration : 40 µg.
Solvent : Dimethyl formamide
Standard drug : ampicillin, amoxicillin, ciprofloxacin,
norfloxacin
The antimicrobial activity was compared with standard drugs viz. ampicillin,
amoxicillin, ciprofloxacin, erythromycin and antifungal activity was compared
with viz. greseofulvin zones of inhibition have been measured in mm.
Antitubercular activity
The antitubercular evaluation of the compounds was carried out at
Tuberculous Antimicrobial Acquisition and Co-ordinating Facility (TAACF) U.S.A.
Method : BACTEC 460 Radiometric System
Bacteria : Mycobacterium tuberculosis H37 Rv
Concentration : 6.25 µg/ml
Standard drug : Rifampin.
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-3-(2',7'-
DICHLOROQUINOLIN-3'-YL)-2-PROPENE 1-ONES
[A] Synthesis of 3-Chloroacetanilide
m-Chloroaniline (12.7 ml) was cooled to 15o to 20oC in 50 ml water. Acetic
anhydride (12.7 ml) was added with stirring and the reaction mixture was heated
under reflux  for 2 and half  hrs. The reaction mixture was poured into ice-
water. The product was isolated and crystallised from methanol. yield 95%;
m.p. 78oC.
[B] Synthesis of 2,7-Dichloroquinolin-3-carboxaldehyde.
Dimethyl formamide (9.13 g, 9.6 ml, 0.125 mol) was cooled to 0oC in a
flask equipped with drying tube and phosphorous oxychloride  (53.7 g, 32.2
ml, 0.35 mol) was added dropwise with stirring. To this solution was added m-
chloroacetanilide (8.5 g, 0.05 mol) and after 5 min. the solution was heated
under refluxed for 6 and half hrs. The reaction mixture was poured into ice-
water and stirred for 30 min.  at 0-10oC. The product was isolated and crystalised
from ethyl acetale yield 54%; m.p. 120oC. Anal calcd. for C10H5NCl2O required
: C, 53.13%; H, 2.23%; N, 6.20%; found: C, 5.9%; H, 1.85%; N, 6.30%
[C] Synthesis of 1-Aryl-3-(2',7'-dichloroquinolin-3'-yl)-2-propene-1-ones
A solution of 4-tolyl acetophenone (2.64 ml, 0.02 mol) in minimum quantity
of ethanol (5 ml) was added to a mixture of 2,7-dichloro quinoline-3-
carboxaldehyde (4.52 g, 0.02 mol) in ethanol (20 ml) and 40% NaOH was added
to make it slightly alkaline. The reaction mixture was then stirred for 24 hrs. at
room temperature. The product was isolated and crystallised from ethanol. yield
63%, m.p. 160oC Anal. calcd. for C19H13NCl2O required; C, 66.68%; H, 3.83%;
N, 4.10% found C, 66.34%; H, 3.68%; N, 4.09%
TLC solvent system: Acetone: Benzene (2.5:7.5) visualizing agent : Iodine
34
Similarly other 1-Aryl-3-(2'-7'-dichloroquinolin-3'-yl)-2-propene-1-ones
were prepared. The physical constants along with infra red spectral data are
recorded in Table No.1a
[D] Therapeutic evaluation of 1-Aryl-3-(2',7'-dichloroquinolin-3'-yl)-2-
propene-1-ones
All the products have been evaluated for their antimicrobial activity as
described under.
(a) Antimicrobial activity104
It was carried out using cup-plate agar diffusion method which has been
described as under.
(i) Antibacterial activity
The purified products were screened for their antibacterial activity. The
nutrient agar broth prepared by usual method was inoculated aseptically with
0.5 ml of 24 hrs. old subculture of B. megaterium. S. aureus,  E. coli and
P. vulgaris  in separate conical flask at 40-50oC and mixed well by gentle shaking.
About 25 ml of the content of the flask were poured and evenly spreaded in a
petridish (13 cm in diameter) and allowed to set for two hrs. The cups (10 mm
in diameter) were formed by the help of borer in agar medium and filled with
0.04 ml (40 µg) solution of sample in DMF.
The plates were incubated at 37oC for 24 hrs and the control was also
maintained with 0.04 ml of DMF in similar manner and the zones of inhibition
of the bacterial growth were measured in millimeters and are recorded in
Graphical Chart No.1
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(ii) Antifungal activity
A. niger was employed for testing antifungal activity using  cup-plate
method. The culture was mainted on Sabouraud's agar slants. Sterilised
Sabouraud's agar medium was inoculated with 72 hrs old 0.5 ml suspension of
fungal spores in a separate flask. About 25 ml of the inoculated medium was
evenly spreaded in a petridish and allowed to set  for two hrs. The cups (10 mm
in diameter) were punched in petridish and loaded with 0.04 ml (40 µg) of
solution of sample in DMF. The plates were incubated at 30oC for 48 hrs. After
the completion of incubation period, the zones of inhibition of growth in the
form of diameter in mm was measured. Along the test solution in each petridish
one cup was filled up with solvent which act as control. The zones of inhibition
are recorded in Graphical Chart No. I.
(iii) Antitubercular activity
The ant i tuberclar evaluat ion of the compouds was car r ied out at
Tuberculosis Antimicrobial Acequisition and Coordination Facility (TAACF),
U.S.A. Primary screening of the compounds for antitubercular activity have been
conducted at 6.25 mg/ml towards Mycobacterium Tuberculosis H37 Rv in
BACTEC 12B medium using the BACTEC 460 radiometric system. The
compounds demonstrating atleast > 90% inhibition in the primary screen have
been retested at lower concentration towards Mycobacterium Tuberculosis H37Rv
to determine the actual minimum inhibitory concentration (MIC) in the BACTEC
460.
The antitubercular activity data have been compared with standard drug
Rifampin at 6.25 µg/ml concentration and it showed 98% inhibition the data for
% inhibition are recorded in Table No. 1b.
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Weight
4
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2
Molecular
Formula
3
M.P.
oC
5
% of Nitrogen
Calcd.
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TABLE NO. 1a : PHYSICAL CONSTANTS OF 1-ARYL-3-(2',7'-ARYL-3-(2',7'-DICHOROQUINOLIN-3'-YL)-2-
PROPENE-1-ONES
Sr.
No.
1
1a C6H5- C18H11NCl2O 328 160 0.589 66 4.23 4.27
1b 3-NH2-C6H4- C18H12N2Cl2O 343 196 0.604 72 8.15 8.16
1c 4-NH2-C6H4- C18H12N2Cl2O 343 146 0.595 61 8.19 8.16
1d 4-Br-C6H4- C18H10NBrCl2O 407 160 0.499 68 3.47 3.44
1e 4-Cl-C6H4- C18H10NCl3O 361.5 120 0.569 56 3.85 3.86
1f 2,6-(OH)2-C6H3- C18H11NCl2O3 360 144 0.575 49 3.92 3.89
1g 4-F-C6H4- C18H10NCl2FO 346 148 0.583 62 4.01 4.05
1h C4H3O- C16H9NCl2O2 318 186 0.541 65 4.42 4.40
1i 2-OH-C6H4- C18H11NCl2O2 344 158 0.589 56 4.08 4.07
1j 4-OH-C6H4- C18H11NCl2O2 344 142 0.607 60 4.04 4.07
1k 4-OCH3-C6H4- C19H13NCl2O2 358 270 0.501 75 3.88 3.91
1l 4-CH3-C6H4- C19H13NCl2O 342 160 0.484 63 4.10 4.09
1m 3-NO2-C6H4- C18H10N2Cl2O3 373 140 0.551 50 7.55 7.51
1n 4-NO2-C6H4- C18H10N2Cl2O3 373 210 0.493 58 7.49 7.51
TLC Solvent System : Acetone : Benzene (2.5 : 7.5).
Rf
Value
6
Yield
%
7
3
7
GRAPHICAL CHART NO. 1 :  1-ARYL-3-(2’,7’-DICHLOROQUINOLIN-3’-YL)-2-PROPENE-1-ONES
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162062 AP-10 4-NH
2
-C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 97 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162058 AP-6 4-OH-C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 69 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162056 AP-4 4-Cl- C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 64 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162060 AP-8 4-F-C
6
H
4
-  S a u r a s h t r a Alamar H37Rv >6.25 64 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162053 AP-1 C
6
H
5
 S a u r a s h t r a Alamar H37Rv >6.25 59 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162055 AP-3 4-OCH
3
-C
6
H
5
 S a u r a s h t r a Alamar H37Rv >6.25 53 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162057 AP-5 4-Br-C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 49 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162054 AP-2 4-CH
3
-C
6
H
4
 S a u rashtra Alamar H37Rv >6.25 46 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162061 AP-9 C
4
H
3
O  S a u r a s h t r a Alamar H37Rv >6.25 31 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162059 AP-7 4-NO
2
- C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 23 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
Dr. A. R. Parikh
Saurashtra University
TABLE NO. 1b  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute
Primary Assay Summary Report
Corp
ID
Sample
ID
Where,  R = Assay MTb
Strain
MIC %
Inhib
CommentSupplier
NCl Cl
R
O
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SECTION - II
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ACETYL-5-(2',7'-
DICHLOROQUINOLIN-3'-YL)-3-ARYL-PYRAZOLINES
1-Acetyl pyrazolines have been found to be associated with diverse
biological activities. These finding prompted us to prepare some new pyrazoline
derivatives of type (II) possessing better biological activity, which have been
prepared by the condensation of chalcones of type (I) with hydrazine hydrate in
acetic acid.
The constitution of the synthesised product has been characterised using
elemental analyses, infra red and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in Part-I, Section- I (D),
antitubercular activity was carried out against Mycobacterium Tuberculosis
H37Rv at a concentration of 6.25 µg using Rifampin as a standard drug.
NCl Cl
R
O
NH2.NH2.H2O
CH3COOH
NCl Cl
N
N
CH3O
R
Type (II) R = Aryl
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IR SPECTRAL STUDY OF 1-ACETYL-3-ρ-TOLYL-5-(2'-7'-DICHLOROQUINOLIN-3'-
YL)-PYRAZOLINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str. 2918 2975-2850 419
C – H def. 1477 1470-1435 "
Aromatic C– H str. 3051 3080-3030 "
C = C str. 1596 1585-1570 "
1477 1520-1480 "
C – H def. 833 835-810 420
Quinoline C = N str. 1598 1612-1593 419
moiety C – Cl str. 727 750-700 "
Pyrazoline C = N str. 1598 1627-1580 418
N–C–CH3- str. 1664 1660 "
41
O
N
Cl
Cl
NN
CH3
O
CH3
PMR SPECTRAL STUDY OF 1-ACETYL-3-(p-TOLYL)-5-(2',7'-DICHLOROQUINOLIN-3'-YL)-
2-PYRAZOLINES
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity J. Value Inference
No. (δ ppm) of Protons in Hz
1 2.39 3H singlet - -COCH3
2. 2.47 3H singlet - -Ar-CH3
3. 3.32-3.40 1H double doublet JAX=5.00 -CHA
JAB=17.76
4. 3.92-4.02 1H double doublet JBX=12.19 -CHB
JBA=17.71
5. 6.04-6.08 1H double doublet JXB=11.21 -CHX
JXA=4.70
6. 7.23-7.26 2H doublet Jhi 7.61 Ar-H'hh'
7. 7.65-7.71 4H multiplate - Ar-H'ii
Ar-Hf
Ar-Hd
8. 8.01-8.04 1H doublet Jgf 8.52 Ar-Hg
9. 8.36 1H singlet - Ar-Ha
42
N
Cl
Cl
NN
CH3
O
CH3
a
gf
d
h
i
h'
i'HX
HB HA
2a C6H5 1656
2b 4-NH2-C6H4 1658
2c 4-Br-C6H4 1658
2d 4-Cl-C6H4 1656
2e 4-F-C6H4 1658
2f C4H3O 1658
2g 2-OH-C6H4 1659
2h 4-OH-C6H4 1660
2i 4-OCH3-C6H4 1656
2j 4-CH3-C6H4 1660
2k 3-NO2-C6H4 1660
2l 4-NO2-C6H4 1658
Sr.
 No. R C=O str.
43
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
IR SPECTRAL DATA OF 1-ACETYL-3-ARYL-5-(2',7'-DICHLOROQUINOLIN-3'-YL)-
PYRAZOLINES
EXPANDED AROMATIC REGION
44
N
Cl
Cl
N
N
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H 3
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ACETYL-3-ARYL-
5-(2',7'-DICHLOROQUINOLIN-3'-YL)-PYRAZOLINES
[A] Synthesis of 1-Aryl-3-(2',7'-dichloroquinolin-3'-yl)-2-propene-1-ones
See part - I, Section-I (C)
[B] Synthesis of 1-Acetyl-3-aryl-5-(2',7'-dichloroquinolin-3'-yl)-
pyrazolines
A mixture of 1-ρ-tolyl-3-(2',7'-dichloroquinolin-3'-yl)-2-propene-1-one (3.43
g, 0.01 mol) in 20 ml acetic acid and hydrazine hydrate (0.59, 0.01 mol) was
refluxed for 10 hrs. The contents were poured onto ice & product was isolated,
crystallised from ethanol yield 56%, m.p. 204oC. Anal. calcd. for C21H17N3Cl2O
required: C, 63.33%; H, 4.3%; N, 10.55%; found: C, 63.20%; H, 4.15%; N,
10.43%.
TLC solvent system: Acetone : Benzene (2:8) visualizing agent : Iodine
Similarly other chalcones were condensed with hydrazine hydrate. The
physical data along with infra red spectral data are recorded in Table Ic.
[C] Therapeutic evaluation of 1-Acetyl-3-aryl-5-(2',7',-dichloroquinolin-
3'-yl)-pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-1 (D).
The zone of inhibition of the test solution are recorded in Graphical Chart No. 2.
The antitubercular activity data have been compared with standard drug rifampin
at 6.25 µg/ml concentration and the data for % inhibition are recorded in Table
No. 1d.
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Molecular
Weight
4
R
2
Molecular
Formula
3
M.P.
oC
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% of Nitrogen
Calcd.
8
Found
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TABLE NO. 1c: PHYSICAL CONSTANTS OF 1-ACETYL-3-ARYL-5-(2',7'-DICHLOROQUINOLIN-3'-YL)-PYRAZOLINES
Sr.
No.
1
2a C6H5- C20H13N3Cl2O 384 90 0.496 56 10.94 10.80
2b 4-NH2-C6H4- C20H16N4Cl2O 399 212 0.550 68 14.03 14.30
2c 4-Br-C6H4- C20H14N3BrCl2O 463 288 0.568 72 9.07 9.29
2d 4-Cl-C6H4- C20H13N3Cl3O 418.5 160 0.801 70 10.04 10.40
2e 4-F-C6H4- C20H14N3Cl2FO 402 218 0.471 64 10.45 10.30
2f C4H3O- C18H13N3Cl2O2 374 98 0.425 69 11.23 11.62
2g 2-OH-C6H4- C20H15N3Cl2O2 400 158 0.569 59 10.50 10.24
2h 4-OH-C6H4- C20H15N3Cl2O2 400 116 0.511 71 10.50 10.27
2i 4-OCH3-C6H4- C21H17N3Cl2O2 414 222 0.623 70 10.14 10.32
2j 4-CH3-C6H4- C21H17N3Cl2O 398 204 0.571 56 10.55 10.43
2k 3-NO2-C6H4- C20H14N4Cl2O3 429 192 0.614 64 13.05 13.29
2l 4-NO2-C6H4- C20H14N4Cl2O3 429 144 0.509 63 13.05 13.38
TLC Solvent System : Acetone : Benzene (2 : 8).
Rf
Value
6
Yield
%
7
4
6
GRAPHICAL CHART NO. 2 :  1-ACETYL-3-ARYL-5-(2’,7’-DICHLOROQUINOLIN-3’-YL)-PYRAZOLINES
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162090 AP-38 4-F-C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 54 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162083 AP-31 C
6
H
5
 S a u r a s h t r a Alamar H37Rv >6.25 39 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
16092 AP-40 4-NH
2
- C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 24 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162084 AP-32 4-CH
3
-C
6
H
4
-  S a u r a s h t r a Alamar H37Rv >6.25 23 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162089 AP-37 4-NO
2
-C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 21 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162086 AP-34 4-Cl-C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 20 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162085 AP-33 4-OCH
3
-C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 14 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162088 AP-36 4-OH-C
6
H
4
 S a u rashtra Alamar H37Rv >6.25 10 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162091 AP-39 C
4
H
3
O  S a u r a s h t r a Alamar H37Rv >6.25 5 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162093 AP-41 2-OH- C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 0 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
Dr. A. R. Parikh
Saurashtra University
TABLE NO. 1c  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute
Primary Assay Summary Report
Corp
ID
Sample
ID
Where,  R = Assay MTb
Strain
MIC %
Inhib
CommentSupplier
NCl Cl
N
N
CH3O
R
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SECTION-III
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1H-3-ARYL-5-(2',7'-
DICHLOROQUINOLIN-3-YL)-PYRAZOLINES
Pyrazoline derivatives are associated with diversified biological properties.
Hence, it was thought of interest that a pyrazoline ring,  if coupled to a 2,7-
dichloroquinolin-3-carboxaldehyde nucleus, the resulting compounds may
possess significant biological potency. Hence the synthesis of 1H-3-aryl-5-(2',7'-
dichloroquinolin-3'-yl)-pyrazolines of type (III) have been undertaken by the
cyclo-condensation of chalcones of the type (I) with hydrazine hydrate.
The constitution of the synthesised products have been characterised by
using elemental analyses, infra red and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg
The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in Part-I, Section-I (D).
NCl Cl
R
O
NCl Cl
N
N
H
R
NH2.NH2.H2O
CH3COOH
Type (III) R = Aryl
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IR SPECTRAL STUDY OF 1H-3-p-TOLYL-5-(2'-7'-DICHLOROQUINOLIN-3'-YL)-
PYRAZOLINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str. 2921 2975-2850 419
C – H def. 1467 1470-1435 "
Aromatic C– H str. 3035 3080-3030 "
C = C str. 1596 1585-1570 "
1514 1520-1480 "
C – H def. 1068 1070-1000 420
831 835-810 "
Quinoline C = N str. 1596 1612-1593 419
moiety C – Cl str. 738 750-700 "
Pyrazoline C = N str. 1614 1627-1580 "
N–H str. 3305 3200-3400 "
50
NCl Cl
N
N
H
CH3
PMR SPECTRAL STUDY OF 1H-3-(ρ-TOLYL)-5-(2',7'-DICHLOROQUINOLIN-3'-YL)-
PYRAZOLINES
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity J. Value Inference
No. (δ ppm) of Protons in Hz
1. 2.41 3H singlet - Ar-CH3
2. 3.06-3.15 1H double doublet JAB=17.76 -CHA
JAX=9.42
3. 3.72-3.79 1H double doublet JBA=17.80 -CHB
JBX=1.82
4. 5.68-5.71 1H double doublet JXA=9.40 -CHX
JXB=1.45
5. 7.26-7.55 2H doublet Jhi 8.15 Ar-H h'h'
6. 7.51-7.55 1H double doublet Jfg 8.76 Ar-Hf
Jfd 2.09
7. 7.79-7.82 1H doublet Jgf 8.75 Ar-Hg
8. 7.85-7.88 2H doublet Jhi 8.14 Ar-H j'j
9. 8.01-8.02 1H doublet Jdf 2.09 Ar-Hd
10 8.49 1H singlet - Ar-Ha
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1H-3-ARYL-5-(2',7'-
DICHLOROQUIOLIN-3'-YL)-PYRAZOLINES
[A] Synthesis of 1-Aryl-3-(2',7'-dichloroquinolin-3'-yl)-2-propene-1-ones
See Part-I, Section I (C).
[B] Synthesis of 1H-3-Aryl-5-(2',7'-dichloroquinolin-3'-yl)-pyrazolines
A mixture of 1-tolyl-3-(2',7'-dichloroquinolin-3'-yl)-2-propene-1-one (3.43
g, 0.01 mol) in 25 ml ethanol, hydrazine hydrate (0.5 g, 0.01 mol) and 2-3
drops of acetic acid was refluxed for 12 hrs. The resulting mixture was poured
into ice and neutralised with ammonia solution. The product was isolated and
crystallised from ethanol. Yield 64%, m.p. 176oC Anal. Calcd. for C19H15N3Cl2
required: C, 64.06%; H, 4.24%; N, 11.80%; found: C, 63.86%; H, 3.99%; N,
11.57%.
TLC solvent system: Acetone: Benzene (1.5 : 8.5) Visualizing agent : Iodine
Similarly other 1H-3-Aryl-5-(2',7'-dichloro quinolin-3-yl)-pyrazolines were
prepared. The physical data along with infra red spectral data are recorded in
Table Ie.
[C] Therapeutic evaluation of 1H-3-Aryl-5-(2',7'-dichloroquinolin-3-yl)-
pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zones of inhibition of the test solution are recorded in Graphical Chart No. 3.
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TABLE NO. 1e: PHYSICAL CONSTANTS OF 1-H-3-ARYL-5-(2',7'-DICHLOROQUINOLIN-3'-YL)-PYRAZOLINES
Sr.
No.
1
3a C6H5- C18H13N3Cl2 342 186 0.485 53 12.28 12.08
3b 4-NH2-C6H4- C18H14N4Cl2 357 210 0.450 59 15.68 15.46
3c 4-Br-C6H4- C18H12N3BrCl2 421 >300 0.568 58 9.98 9.65
3d 4-Cl-C6H4- C18H12N3Cl3 375.5 240 0.612 60 11.16 11.55
3e 4-F-C6H4- C18H12N3Cl2F 360 172 0.520 62 11.67 10.27
3f 2-OH-C6H4- C18H13N3Cl2O 358 236 0.741 57 11.73 11.99
3g 4-OH-C6H4- C18H13N3Cl2O 358 160 0.639 66 11.73 11.58
3h 4-OCH3-C6H4- C19H15N3Cl2O 372 184 0.580 69 11.29 11.65
3i 4-CH3-C6H4- C19H15N3Cl2 356 176 0.565 64 11.80 11.57
3j 3-NO2-C6H4- C18H12N4Cl2O2 387 136 0.419 70 14.47 14.95
3k 4-NO2-C6H4- C18H12N4Cl2O2 387 216 0.678 55 14.47 14.05
TLC Solvent System : Acetone : Benzene (1.5 : 8.5).
Rf
Value
6
Yield
%
7
5
5
GRAPHICAL CHART NO. 3  :    1H-3-ARYL-5-(2’,7’-DICHLOROQUINOLIN-3’-YL)-PYRAZOLINES
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PART - II
STUDIES ON
CYANOPYRIDINES
57
INTRODUCTION
Historically, a wide range of biological activities have been attributed to
pyridine derivatives. Pyridine-3-carboxamide occurs as a component of the
structure of the important coenzymes NADP + (I), one of the B2 complex of
vitamins, occurs in red blood carpuscles and participates in biochemical redox
reaction. Pyridoxal (Vitamin B6) (II), occurs in yeast and wheatgerm is an
important food additive.
The availability of 3-cyanopyridine, nicotinamide and nicotinic acid make
possible their use as synthetic intermediates.
SYNTHETIC ASPECT
Different methods for the preparation of 3-cyanopyridines are available in
literature105-111. The well known method is:
Sakurai and Midorikwa112,113 have reported that malononitrile reacts with
α,β unsaturated ketones to give 2-amino-3-cyano-4,6-disubstituted pyridines (III).
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CH2OHOH
CH3
(I) R =  PO(OH)2
(II)
Cyanopyridines...
MECHANISM:
The reaction proceeds through conjugated addition of active methylene
compounds to the α,β-unsaturated system as shown below.
THERAPEUTIC IMPORTANCE
The cyanopyridine derivatives are extensively used in medicine, due to its
antidiabetic, antihypertensive, anticholestemic, antifungal and antibacterial
properties. Various cyanopyridines are known to exhibit a broad spectrum of
biological activities such as,
1. Anti HIV114
2. Antitubercular115
3. Analgesic116
4. Insecticidal117
5. Antisoriasis118
OR'
O
R
CH2(CN)2
N
R
N
NH2
R'
(III)
Cyanopyridines...
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6. Antihypertensive119
7. Antifungal120
8. Antiepileptic121
9. Anticonvulsant122
10. Antibacterial123,124
11. Antiinflammatory125
Gangjee et al.126 have synthesised some novel cyanopyridine derivatives
of type-(IV) as potent antitumor agents.
The insecticidal activity of cyanopyridines has been screened by Y. Sasaki
et al.127 Umed Ten et al.128 have prepared cyanopyridines as agrochemical
fungicides. The oxide activator bleaching activity of cyanopyridine has been
proved by Rees M.129 Oshida Mario130 prepared cyanopyridine derivatives
which inhibit cerebral edema and delayed neuron death. Hence, they are useful
as cerebral edema inhibitors as cerebrovascular disorder remedies.
Several co-workers have prepared some novel cyanopyridine derivatives
and repor ted the i r  cho l ines te rase  inh ib i tors131,  ant ih i s tamin ic  and
antiallergic132, adernegic133, herbicidal134, antiinflammatory135, and
insecticidal136 activities.
Chambers et al.137 have synthesised new carbonyl substituted pyridine
derivatives (V) and prooved that they are inhibitors of phosphodiestercy (IV)
isozymes.
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N
N
NH2
Z
R'
(IV)
R' =  H, 2-OMe, 4-OMe, 4-Cl
Z = -NH, -N-CH3
Some new 3-cyanopyridine derivatives have been prepared by Hammama
A. and co-workers138 showing anticancer and anti HIV-I activity.
CONTRIBUTION FROM OUR LABORATORY
H. Parekh et al.139-141 have synthesised the series of cyanopyridines and
postulated them as antimicrobial agents. A. R. Parikh et al.142 have prepared
some new cyanopyridines and studied their antimicrobial activity. H. H. Parekh
et al.143 have synthesised 3-cyanopyridines bearing quinoline nucleus and tested
their antimicrobial and antitubercular activity.
Abdallah N. et al.144 have prepared cyanopyridine derivatives which
showed analgesic and antiinflammatory activity. Ladouceur Getan H. et al.145
have synthesised some new pyridine derivatives behaving as glucagon
antagonist. Caroline Charlie and co-worker146 have prepared pyridine
derivatives having antiinflammatory activity. Antimicrobial activity of 3-
cyanopyridine derivatives have been studied by Mona Komel et al.147
In view of the above observations, the synthesis of new 3-cyanopyridine
derivatives bearing 2,7-dichloroquinoline moiety, were aimed at investigating
biological activities of these compounds.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
2-AMINO-3-CYANO-4-(2',7'-DICHLOROQUINOLIN-
3'-YL)-6-ARYL PYRIDINES
N
NH
O F
O
OR
O
O
O
O (V) R =  Aryl
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-AMINO-3-
CYANO-4-(2',7'-DICHLOROQUINOLIN-3'-YL)-6-ARYL PYRIDINES
A perusal  of  the l i terature has revealed manifold impl icat ions of
cyanopyridines, viz.  antibacterial ,  anti fungal,  and antial lergic etc. The
cyanopyridine derivatives are endowed with variety of pharmacological activities.
In view of these findings, i t  was contemplated to synthesise some new
cyanopyridine derivatives bearing 2,7-dichloroquinolin-3-carboxaldehyde moiety
and assess their biopotential. The synthesis was carried out by the condensation
of chalcones of type (I) with malononitrile and ammonium acetate.
The constitution of the synthesised products have been characterised using
elemental analyses, infra red and 1H nuclear magnetic resonance spectroscopy
and further supported by mass-spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/
ml. The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in Part-I, Section-I (D).
NCl Cl
R
O
NCl Cl
N
R
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N
Type (IV) R = Aryl
CH2(CN)2
CH3COONH4
IR SPECTRAL STUDY OF 2-AMINO-3-CYANO-4-(2',7'-DICHLOROQUINOLIN-3'-YL)-
6-p-ANISYL PYRIDINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str. (asym) 2923 2975-2950 419
-CH3 C – H str. (sym) 2850 2880-2860 "C – H def. (asym) 1442 1470-1435 "
C – H def. (sym) 1361 1385-1370 "
Aromatic C– H str. 3088 3080-3030 "
C = C str. 1576 1585-1570 "
1512 1520-1480 "
C – H i.p.def. 1076 1125-1090 420
1026 1070-1000 "
C – H. o.o.p. def. 835 835-810 "
Quinoline C = N str. 1622 1612-1593 419
moiety C – Cl str. 744 750-700 "
Pyridine C = H str. 3088 3080-3030 "
C = C  str. 1622 1650-1520 "
(overlaped)
C = N str. 1573 1580-1550 "
(overlaped)
Nitrile C = N str. 2202 2240-2220 "
Ether C – O – C str. 1249 1275-1200 418
N-H str. 3330 3400-3250 419
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NCl Cl
N
NH2
N
OCH3
PMR SPECTRAL STUDY OF 2-AMINO-3-CYANO-4-(2',7'-DICHLOROQUINOLIN-3'-YL)-
6-(p-TOLYL)-PYRIDINES
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity J. Value Inference
No. (δ ppm) of Protons in Hz
1. 2.4 3H singlet - Ar-CH3
2. 6.89-6.92 2H doublet Jih 8.08 Ar-H i,i'
3. 7.28-7.29 1H doublet Jdf 1.37 Ar-Hd
4. 7.31 1H singlet - Ar-HX
5. 7.39-7.42 2H doublet Jhi 8.51 Ar-H h,h'
6. 7.45-7.46 1H double doublet Jfg 7.96 Ar-Hf
Jfd 1.47
7. 7.51-7.54 1H doublet Jgf 7.34 Ar-Hg
8. 9.70 1H singlet - Ar-Ha
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NCl Cl
N
NH2
N
CH3
g
f
d
a
X
h
i
h'
i'
4a C6H5 2200
4b 4-NH2-C6H4 2198
4c 4-Br-C6H4 2202
4d 4-Cl-C6H4 2210
4e 4-F-C6H4 2198
4f C4H3O 2196
4g 2-OH-C6H4 2198
4h 4-OH-C6H4 2200
4i 4-OCH3-C6H4 2202
4j 4-CH3-C6H4 2202
4k 3-NO2-C6H4 2204
4l 4-NO2-C6H4 2202
Sr.
 No. R
C=N str.
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
IR SPECTRAL DATA OF 2-AMINO-3-CYANO-4-(2',7'-DICHLOROQUINOLIN-3'-YL)-
6-ARYL PYRIDINES
EXPANDED AROMATIC REGION
64
65
N
C
l
C
l
N
N
H
2
N m
/z
 =
 3
9
1
EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-AMINO-3-
CYANO-4-(2',7'-DICHLOROQUINOLIN-3'-YL)-6-ARYL-PYRIDINES
[A] Synthesis of 1-Aryl-3-(2',7'-dichloroquinolin-3'-yl)-2-propene-1-
ones.
See part (I) Section - I (C).
[B] Synthesis of 2-Amino-3-cyano-4-(2',7'-dichloroquinoline-3'-yl)-6-
aryl-pyridines
A mixture of 1-p-tolyl-3-(2',7'-dichloroquinolin-3'-yl)-2-propene-1-one (342
g, 0.01 mol), malononitrile (1.29 g, 0.01 mol) and ammonium acetate (9.24 g.
0.12 mol) dissolved in absolute alcohol (50 ml) were heated under reflux for 12
hrs., cooled and poured into crushed ice. The product separated was filtered
and recrystallised from ethanol. Yield 52%, m.p 162oC; Anal. Calcd. for
C22H14N4Cl2 required : C, 65.20%; H, 3.48%; N, 13.82%; found : C, 65.25%;
H, 3.45%; N, 13.58%.
TLC Solvent System : Acetone : Benzene (10:0), Visualizing Agent : Iodine.
Similarly, other 2-amino-3-cyano-4-(2',7'-dichloroquinolin-3'-yl)-6-aryl-
pyridines were prepared. The physical data along with infra red spectral data
are recorded in Tabel No. 2a.
[C] Therapeutic evaluation of 2-Amino-3-cyano-4-(2',7'-dichloro
quinolin-3'-yl)-6-aryl-pyridines
Antimicrobial testing was carried out as described in Part-I, Section-I
(D). The zone of inhibition of the test solution are recorded in Graphical Chart
No. 4. The antitubercular activity data have been compared with standard drug
rifampin at 6.25 µg/ml concentration and the data for % inhibition are recorded
in Table No. 2b.
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Molecular
Weight
4
R
2
Molecular
Formula
3
M.P.
oC
5
% of Nitrogen
Calcd.
8
Found
9
TABLE NO. 2a : PHYSICAL CONSTANTS OF 2-AMINO-3-CYANO-4-(2',7'-DICHLOROQUINOLIN-3'-YL)-6-ARYL-
PYRIMIDINES
Sr.
No.
1
4a C6H5- C21H12N4Cl2 391 192 0.413 63 14.32 14.67
4b 4-NH2-C6H4- C21H15N5Cl2 406 182 0.477 53 17.24 17.64
4c 4-Br-C6H4- C21H11N4BrCl2 470 198 0.550 54 11.92 11.65
4d 4-Cl-C6H4- C21H11N4Cl3 425.5 104 0.509 58 13.16 13.50
4e 4-F-C6H4- C21H11N4Cl2F 409 162 0.635 56 13.69 13.93
4f C4H3O- C19H10N4Cl2O 381 202 0.521 59 13.70 14.88
4g 2-OH-C6H4- C21H12N4Cl2O 407 184 0.487 61 13.76 13.99
4h 4-OH-C6H4- C21H12N4Cl2O 407 166 0.620 63 13.76 13.51
4i 4-OCH3-C6H4- C22H14N4Cl2O 421 122 0.537 60 13.30 13.64
4j 4-CH3-C6H4- C22H14N4Cl2 405 162 0.566 52 13.82 13.58
4k 3-NO2-C6H4- C21H11N5Cl2O2 436 152 0.498 51 16.50 16.77
4l 4-NO2-C6H4- C21H11N5Cl2O2 436 >250 0.538 57 16.50 16.83
TLC Solvent System : Acetone : Benzene (10 : 0).
Rf
Value
6
Yield
%
7
6
7
GRAPHICAL CHART NO. 4 :         2-AMINO-3-CYANO-4-(2’,7’-DICHLOROQUINOLIN-3’-YL)-6-ARYL PYRIDINES
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162100 AP-48 4-F-C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 93 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162095 AP-43 4-CH
3
-C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 64 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162096 AP-44 4-OCH
3
- C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 57 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162098 AP-46 4-OH-C
6
H
4
-  S a u r a s h t r a Alamar H37Rv >6.25 44 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162099 AP-47 4-NO
2
-C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 32 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162097 AP-45 4-Br-C
6
H
4
 S a u r a s h t r a Alamar H37Rv >6.25 30 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
162101 AP-49 C
4
H
3
O  S a u r a s h t r a Alamar H37Rv >6.25 25 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
Dr. A. R. Parikh
Saurashtra University
TABLE NO. 2a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute
Primary Assay Summary Report
Corp
ID
Sample
ID
Where,  R = Assay MTb
Strain
MIC %
Inhib
CommentSupplier
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NCl Cl
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PART - III
STUDIES ON
CYANOPYRIDONES
INTRODUCTION
Biosignificant pyridones form a component in a number of useful drugs
and are associated with many biological, pharmaceutical and therapeutic
activities. Pyridones, with a carbonyl group at position 2(I) have been subject
of extensive study in the recent years. Numerous reports have appeared in the
literature which highlight their chemistry and use.
2-Pyridones are derivatives of pyridine with carbonyl group at 2-position(I),
some 2-pyridones, which are pharmacologically important are as under: eg.
amrinone(II), ciclopirox(III) and methylphylone (IV).
Synthetic pyridone derivatives contribute much to the searchable literature
of pyridone derivatives in huge libraries owing to their wide applicability in
different fields.
Cyanopyridones...
( I )
N
H
O
N
H
NH2
N
O N
H
O
O
C2H5
C2H5
CH3
N
H
O
CH3
( II ) ( III ) ( IV )
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SYNTHETIC ASPECT :
Different methods for the preparation of 2-pyridones are as under.
1. S. A. Harris and K. Falkers148 have reported 3-cyano-2-pyridone by the
condensation of cyanoacetamide with 1,3-diketone or β-ketoester.
2. M. A. Slwyter et al.149 have prepared fused 2-pyridones.
3. G. Simchen and G. Entemann150 have synthesised 2-pyridone in which
the ring nitrogen comes from a nitrile group in acyclic precursor. Addition
of HCl to the nitrile produces an imidoyl chloride which can cyclize.
MECHANISM
The addition reaction between ethylcyanoacetale and α,β-unsaturated
ketone give cyanopyridone via Michael addition. Here, α,β−unsaturated
compound is known as acceptor and active methylene group containing
compound known as addender. It involves nucleophillic addition of carbanion
to the C=C of the acceptor.
N
H
CH2OC2H5
N
O
CH3
O
NH2
N
+
O
CH3
H5C2OH2C
O
R R'
O
CNCH2COOC2H5
CH3COONH4
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OH
R'
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R
NH2
O
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R'
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C
C
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C
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R'
N
R
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THERAPEUTIC IMPORTANCE
Literature survey reveals that various pyridones having potential of drugs
are known to exhibit a broad spectrum of biological activities such as:
1. Anticancer151
2. Antimicrobial152
3. Pesticidal153
4. Angitensin II antagonistic154
5. Herbicidal155
6. Antiviral156
7. Antibacterial157
Peter et al.158 have prepared pyridinylmethyl substituted pyridines and
pyridones as angiotensin II antagonists. H. Poner159 reported 2-pyridones as
physiological ly active compounds. Coll ins and co-workers160 prepared
heteroaryl pyridones as GABA α2/α3 ligands (V).
More over, several co-workers have pre-reported 2-pyridones as S3 site of
thrombin inh ib i tor161,  herb ic ida l162,  SH2 domain inh ib i tor
163,
antimicrobial164, GABA-A reccptor165 and antiiinflammatory166.
Mukhta Hussain Khan and co-workers167,168 have synthesised 2-pyridone
derivatives (VI) and (VII) which possess insecticidal and pesticidal activity.
NH
O
X
Y
Z
( V )
Cyanopyridones... 72
E. Amer169 reported 3-cyano-2-pyridone derivatives, displaying high
antimicrobial activity. Abou El-Fotooh et al.170 have demonstrated pyridones
as anticancer agent. F. Paala171 synthesised 2-pyridone derivatives (VIII),
showing good cardiotonic activity. Gulcan Ozturk et al.172 described 1,2,5-
substituted-4-pyridone derivatives having analgesic and antiinflammatory
activity. Tanaka A. and co-workers 173 reported 2-pyridone derivatives (IX and
X) which showed adenosine antagonist activity and anticatalepsy activity.
Thus, significant biological properties associated with pyridones, have
aroused considerable interest to design the compounds with a view to get better
drug potential, to study their pharmacological profile, which have been described
as under.
SECTION-I : SYNTHESIS AND THERAPEUTIC EVALUATION OF 1,2-
DIHYDRO-3-CYANO-4-(2',7'-DICHLOROQUINOLIN-3'-
YL)-6-ARYL-2-PYRIDONES
Cyanopyridones...
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1,2-DIHYDRO-3-
CYANO-4-(2',7'-DICHLOROQUNOLIN-3'-YL)-6-ARYL-2-PYRIDONES
During the last few years, interest in the use of cyanopyridone derivatives
in medicine and agriculture has greatly increased. To further assess the potential
of such a class of compounds as antimicrobial agents, a series of cyanopyridone
of type (V) have been synthesised by the condensation of chalcones of type(I)
with ethyl cyanoacetale in presence of ammonium acetate as under.
The constitution of the synthesised products have been characterised using
elemental analyses, infra red and 1H nuclear magnetic resonance spectroscopy
and further supported by mass-spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in  Part-I, Section-I (D).
NCl Cl
R
O
R = Aryl
CNCH2COOC2H5
CH3COONH4
NCl Cl
NH
R
O
N
Type (V)
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IR SPECTRAL STUDY OF 1,2-DIHYDRO-3-CYANO-4-(2',7'-DICHLOROQUINOLIN-
3'-YL)-6-p-TOLYL-2-PYRIDONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str. 2925 2975-2950 419
–CH3 C – H def. (asym) 1477 1470-1435 "
Aromatic C– H str. 3082 3090-3030 "
C = C str. 1512 1550-1480 "
C – H.i.p. def. 1139 1125-1090 420
C – H. o.o.p. def. 829 835-810 "
Quinoline C = N str. 1606 1612-1593 419
moiety C – Cl str. 773 750-700 "
Pyridone N – H str. 3401 3400-3250 "
ring C = N str. 2218 2250-2120 "
C = O str 1651 1780-1655 "
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PMR SPECTRAL STUDY OF 1,2-DIHYDRO-3-CYANO-4-(2',7'-DICHLOROQUINOLIN-3'-
YL)-6-(p-METHOXYPHENYL)-2-PYRIDONES
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity J. Value Inference
No. (δ ppm) of Protons in Hz
1. 3.88 3H singlet - Ar-OCH3
2. 6.62 1H singlet -` Ar-HX
3. 7.00-7.03 2H doublet Jin 8.83 Ar-Hi,i'
4. 7.64-7.67 1H doublet doublet Jfg 8.78 Ar-Hf
5. 7.78-7.81 2H doublet Jhi 8.79 Ar-Hh,h'
6. 7.97-8.00 1H doublet Jgf 8.77 Ar-Hg
7. 8.05 1H singlet - Ar-Hd
8. 8.37 1H singlet - Ar-Ha
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NCl Cl
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g
f
d
a h
i
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X
5a C6H5 2218 1649
5b 3-NH2-C6H4 2218 1651
5c 4-NH2-C6H4 2210 1649
5d 4-Br-C6H4 2216 1649
5e 4-Cl-C6H4 2220 1649
5f 2,6-(OH)2-C6H3 2218 1651
5g 4-F-C6H4 2218 1651
5h 2-OH-C6H4 2216 1651
5i 4-OH-C6H4 2218 1649
5j 4-OCH3-C6H4 2210 1649
5k 3-CH3-C6H4 2218 1651
5l 3-NO2-C6H4 2210 1649
5m 4-NO2-C6H4 2215 1652
Sr.
 No. R –C=N C=O
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
IR SPECTRAL DATA OF 1,2-DIHYDRO-3-CYANO-4-(2',7'-DICHLOROQUINOLIN-3'-
YL)-6-ARYL-2-PYRIDONES
EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1,2-DIHYDRO-3-
CYANO-4-(2',7'-DICHLOROQUINOLIN-3'-YL)-6-ARYL-2-PYRIDONES
[A] Synthesis of 1-Aryl-3-(2',7'-dichloroquinolin-3'-yl)-2-propene-1-ones
See Part (I), Section-I(C).
[B] Synthesis of 1,2-Dihydro-3-cyno-4-(2',7'-dichloroquinolin-3-yl)-6-
aryl-2-pyridones
1-p-Tolyl-3-(2',7'-dichloroquinolin-3'-yl)-2-propene-1-one (3.42g 0.01mol)
was dissolved in ethanol (50 ml). Add ethylcyanoacetate (1.13g. 0.01mol) and
ammonium acetate (9.24g. 0.12 mol) to it. The mixture was then heated under
reflux for 8 hrs. The product separated was filtered and recrystallised from
methanol. Yield. 57%, m.p. 224oC; Anal. calcd for C22H13N3Cl2O : C, 65.04%;
H, 3.23%; N, 10.34%; Found : C, 65.07%; H, 3.25%; N, 9.93%.
TLC solvent system: Acetone: Benzene (0.5: 9.5) Visulizing Agent : Iodine.
Similarly, other 1,2-Dihydro-3-cyano-4-(2',7'-dichloroquinolin-3'-yl)-6-aryl-
2-pyridones were prepared. The physical data along with infra red spectral data
are recorded in Table No. 3
[C] Therapeutic evaluation of 1,2-Dihydro-3-cyano-4-(2',7'-dichloro
quinolin-3'-yl)-6-aryl-2-pyridones
Antimicrobial testing was carried out as described in Part-I, Section-I(D).
The zones of inhibition of the felt solution are recorded in Graphical Chart No. 5.
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TABLE NO. 3 : PHYSICAL CONSTANTS OF 1,2-DIHYDRO-3-CYANO-4-(2',7'-DICHLOROQUINOLIN-3'-YL)-6-ARYL-
2-PYRIDONES
Sr.
No.
1
5a C6H5- C21H11N3Cl2O 392 124 0.534 63 10.71 10.29
5b 3-NH2-C6H4- C21H12N4Cl2O 407 158 0.405 61 13.76 13.35
5c 4-NH2-C6H4- C21H12N4Cl2O 407 204 0.435 59 13.76 13.99
5d 4-Br-C6H4- C21H10N3BrCl2O 471 172 0.585 58 8.92 8.54
5e 4-Cl-C6H4- C21H10N3Cl3O 426.5 170 0.609 59 9.85 9.57
5f 2,6-(OH)2-C6H3- C21H11N3Cl2O3 424 168 0.659 60 9.90 9.63
5g 4-F-C6H4- C21H10N3Cl2FO 410 148 0.714 55 10.24 10.51
5h 2-OH-C6H4- C21H11N3Cl2O2 408 202 0.650 54 10.29 10.59
5i 4-OH-C6H4- C22H11N3Cl2O2 408 150 0.473 56 10.29 10.05
5j 4-OCH3-C6H4- C22H13N3Cl2O2 422 176 0.512 58 9.95 9.69
5k 4-CH3-C6H4- C22H13N3Cl2O 406 224 0.591 57 10.34 9.93
5l 3-NO2-C6H4- C21H10N4Cl2O3 437 184 0.481 60 12.81 12.69
5m 4-NO2-C6H4- C21H10N4Cl2O3 437 196 0.541 62 12.81 12.97
TLC Solvent System : Acetone : Benzene (0.5 : 9.5).
Rf
Value
6
Yield
%
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GRAPHICAL CHART NO. 5 : 1,2-DIHYDRO-3-CYANO-4-(2’,7’-DICHLOROQUINOLIN-3’-YL)-6-ARYL-2-PYRIDONES
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PART - IV
STUDIES ON
BARBITONES
INTRODUCTION
Barbituric acid derivatives have gained prominance because of their
potential pharmaceutical values. Many barbituric acid derivatives play vital role
in many physiological action. Most important is the effect of barbiturates on the
central nervous system. There are more than 40 synthetic drugs bearing barbituric
acid, in use recently. They possess diverse type of biological properties including
hypnotic, sedatives, anticonvulsant, cardiovascular etc. The first member of
hypnotic drugs series was barbital (I).
Barbituric acid ring system has been found in many natural products like
alkaloids, which includes Xanthine (II) and Theophyline (III) are constituents of
tea leaves. Theobromine is found in cocoa beans.
SYNTHETIC ASPECT
Dif ferent  methods are used for  the preparat ion of  barbi tones in
literature174,175.
1. Cao-Yun Weu et al.176 have prepared barbituric acid derivatives by the
reaction of different aldehydes with barbituric acid in basic media.
Barbitones...
NHNH
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O
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NHNH
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2. M. R. Mahmoud et al.177 have synthesised barbituric acid derivatives from
chalcone.
3. Ogus Funda et al.178 have synthesised barbiturates by the reaction between
acetone and barbituric acid.
THERAPEUTIC IMPORTANCE
Barbituric acid derivatives demonstrate a very broad spectrum of biological
activity, because of their structural relationship with nucleic acids, viz. uracil,
thymine and cytosine. Perhaps barbituric acid derivatives are most widely used
pyrimidines in medicinal chemistry.
Phenobarbitone (IV) possess sedative and hypnotic activities, thiopentone
(V) is a useful local anaesthetic while Eterobarb (VI) is an anticonvulsant drug.
Carbubarb179 is a barbituric acid derivative, which is used as a veternary
anaesthetics. Some isoxazole pyrimidine derivatives have been studied because
of their potential as as pesticidal180,181 activity. Some barbiturates showing
cardiovascular182-184 and analgesic and antiinflammatory activities185 have
been reported.
NHNH
O
O
O
R R'
gla. acetic acid
NHNH
O
O
O
+R
R'
O
Barbitones...
NH
NO S
O
CH2OCH3
H5C2
CH3 CH3
NH
N
H
O O
O
H5C2 N
NO O
O
CH2OCH3
CH2OCH3
H5C2
(VI)(V)(IV)
83
Ulf Wellmar et al.186 have synthesised some uracil derivatives and screened
for antiviral activity187,188. Raymond et al.189 investigated some barbiturates
(VII), showing anticancer activity while Mahmoud et al.190 reported their
antimicrobial activity.
Some isoxazolo pyrimidine derivatives have been extensively studied and
reported as antagonist191 and antitumor192 agents. Agricultural activity of 5-
(3-benzylthiazolidine-2-ylidene)-1,3-dimethyl hexahydro pyrimidine-2,4,6-trione
was reported by Wolf-Gang et al.193 Harbicidal and insecticidal activity of
barbiturates was documented by Andre Roland and co-workers194. Omar M.
T.195 have showed barbitone derivatives demonstrating antimicrobial activity.
Sakai and co-workers196 has synthesised some new barbitones which are
assessed for bone and cartilage diseases. R. T. Pardasani and co-workers197
have described some new isatylidene barbitones (VIII) and tested their
antibacterial activity.
Vital contribution of barbituric acid ring system to the medicinal chemistry
as an active constituent of hypnotics and sedatives made chemists to explore
for its other derivatives as therapeutic agents. Accordingly several derivatives
of barbituric acid have been designed as under.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
[1-ARYL-3-(2',7'-DICHLOROQUINOLIN-3'-YL]-2-
PROPENYLIDENE]-5-BARBITURIC ACIDS
Barbitones...
(VIII)
R' = Alkyl / X / H
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H
NH H
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF [1-ARYL-3-(2',7'-
DICHLOROQUINOLIN-3'-YL]-2-PROPENYLIDENE]-5-BARBITURIC
ACIDS
Barbiturates are known to play an important role in medicinal chemistry
because of their effect on central nervous system. The first member of hypnotic
drugs series was barbital. Considering this background, some new barbituric
acid derivatives of type (VI) were prepared by the condensation of compounds
of type (I) with barbituric acid in glacial acetic acid.
The constitution of the synthesised products have been characterised using
elemental analyses, infra red and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in  Part-I, Section-I (D).
NCl Cl
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Type (VI) R = Aryl
NCl Cl
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Barbituric Acid
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IR SPECTRAL STUDY OF [1-p-NITROPHENYL-3-(2',7'-DICHLOROQUINOLIN-3'-YL)-
2-PROPENYLIDENE]-5-BARBITURIC ACID
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str. (asym) 2925 2975-2950 419
–CH3 C – H def. (sym) 1490 1470-1435 "
Aromatic C– H str. 3010 3080-3030 "
C = C str. 1512 1520-1480 "
C – H.i.p. def. 1143 1150-1090 420
C – H. o.o.p. def. 827 835-810 "
Quinoline C = N str. 1627 1650-1590 419
moiety C – Cl str. 736 750-700 "
Barbitone N – H str. 3261 3350-3140 422
C = O str. 1708 1750-1700 "
Vinyl HC= CH str. 3010 3050-3000 "
N – O str. 827 850-810 "
NCl Cl
NH
N
H
O
O
O
NO2
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PMR SPECTRAL STUDY OF [1-(p-ANISYL)-3-(2',7'-DICHLOROQUINOLIN-3'-YL)-2-
PROPENYLIDINE]-5-BARBITURIC ACID
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity J. Value Inference
No. (δ ppm) of Protons in Hz
1. 3.9 3H singlet - Ar-OCH3
2. 7.03-7.06 2H doublet Jih 8.51 Ar-H i,i'
3. 7.17-7.20 1H doublet Jfg 8.06 Ar-Hf
4. 7.40 1H singlet - Ar-Hd
5. 7.65-7.68 1H doublet Jgf 8.47 Ar-Hg
6. 7.74-7.78 1H doublet JBA 13.14 -CHB
7. 8.06-8.09 2H doublet Jhi 8.58 Ar-H h,h'
8. 8.32-8.36 1H doublet JAB 12.71 -CHA
9. 8.41 1H singlet - Ar-Ha
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6a C6H5 1706
6b 3-NH2-C6H4 1708
6c 4-NH2-C6H4 1710
6d 4-Br-C6H4 1706
6e 4-Cl-C6H4 1710
6f 2,6-(OH)2-C6H3 1700
6g 4-F-C6H4 1710
6h 2-OH-C6H4 1708
6i 4-OH-C6H4 1706
6j 4-OCH3-C6H4 1710
6k 4-CH3-C6H4 1708
6l 4-NO2-C6H4 1710
6m 4-NO2-C6H4 1708
Sr.
 No. R C=O str.
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
IR SPECTRAL DATA OF [1-ARYL-3- (2 ' ,7 ' -DICHLOROQUINOLIN-3 ' -YL) -2-
PROPENYLIDENE]-5-BARBITURIC ACIDS
EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF [1-ARYL-3-(2',7'-
DICHLOROQUINOLIN-3'-YL]-2-PROPENYLIDENE]-5-BARBITURIC
ACIDS
[A] Synthesis of 1-Aryl-3-(2',7'-dichloroquinolin-3'-yl)-2-propene-1-ones
See Part - (I), Section - I (C).
[B] Synthesis of [1-Aryl-3-(2',7'-dichloroquinolin-3'-yl)-2-propenylidine]
-5-barbituric acids
A mixture of 1-p-tolyl-3-(2',7'-dichloroquinolin-3'-yl)-2-propene-1-ones
(3.42g. 0.01 mol) and barbituric acid (1.28 g., 0.01 mol) in glacial acetic acid
was refluxed for 12 hrs. The contents were poured into ice and product was
isolated, crystallised from ethanol. Yield 54%, m.p. 270oC, Anal. Calcd for
C23H15N3Cl2O3 required : C, 60.81%; H, 3.77%; N, 9.25%; found : C, 60.85%;
H, 3.75%; N, 9.53%.
TLC Solvent system : Acetone : Benzene (1:9) visulising Agent : Iodine.
Similarly, other [1-Aryl-3-(2',7'-dichloroquinolin-3'-yl)-2-propenylidine]-5-
barbituric acids were prepared. The physical data along with infra red spectral
data are recorded in Table No. 4.
[C] Therapeutic evaluation of [1-Aryl-3-(2',7'-dichloroquinolin-3'-yl)-2-
propenylidine]-5-barbituric acids
Antimicrobial testing was carried out as described in Part-I, Section-I
(D). The zones of inhibition of the test solutions are recorded in Graphical
Chart No. 6.
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TABLE NO. 4 : PHYSICAL CONSTANTS OF [1-ARYL-3-(2',7'-DICHLOROQUINOLIN-3'-YL)-2-PROPENYLIDENE]-5-
BARBITURIC ACIDS
Sr.
No.
1
6a C6H5- C22H13N3Cl2O3 438 212 0.686 53 9.54 9.19
6b 3-NH2-C6H4- C22H14N4Cl2O3 453 234 0.652 51 12.31 12.59
6c 4-NH2-C6H4- C22H14N4Cl2O3 453 214 0.565 54 12.31 11.98
6d 4-Br-C6H4- C22H12N3BrCl2O3 517 298 0.489 56 8.09 8.23
6e 4-Cl-C6H4- C22H12N3Cl3O3 472.5 286 0.580 57 8.85 8.57
6f 2,6-(OH)2-C6H3- C22H13N3Cl2O5 470 280 0.691 56 8.90 8.64
6g 4-F-C6H4- C22H12N3Cl2FO3 456 276 0.666 55 9.17 9.43
6f 2-OH-C6H4- C22H13N3Cl2O4 454 274 0.613 59 9.21 9.39
6h 4-OH-C6H4- C22H13N3Cl2O4 454 266 0.602 57 9.21 9.51
6j 4-OCH3-C6H4- C23H15N3Cl2O4 468 288 0.549 58 8.93 8.69
6k 4-CH3-C6H4- C23H15N3Cl2O3 452 270 0.586 54 9.25 9.53
6l 3-NO2-C6H4- C22H12N4Cl2O5 483 296 0.494 53 11.55 11.80
6m 4-NO2-C6H4- C22H12N4Cl2O5 483 290 0.439 52 11.55 11.83
TLC Solvent System : Acetone : Benzene (1 : 9).
Rf
Value
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GRAPHICAL CHART NO. 6 :  [1-ARYL-3-(2’,7’-DICHLOROQUINOLIN-3’-YL)-2-PROPENYLIDENE]-5-BARBITURIC ACIDS
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PART - V
STUDIES ON
ISOXAZOLES
INTRODUCTION
Isoxazoles offer a wide range of applications in medicinal field, as they
are associated with a broad spectrum of biological activity. The investigation of
isoxazole was made in 1888, by Claisen, who named isoxazole (I) for a product
obtained by the reaction of 1,3-diketone with hydroxylamine198. There after,
Claisen and his students form a strong foundation for the chemistry of isoxazoles.
Isoxazole possess typical properties of an aromatic system but under certain
reaction conditions, particularly in reducing or basic media, it becomes highly
labile.
A huge role in the chemistry of isoxazoles was played by Quelico in 1946,
when he began to study the formation of isoxazoles from nitrile N-oxides and
unsaturated compounds199.
SYNTHETIC ASPECT
The construction of isoxazole ring was carried out by the reaction of
hydroxylamine with α,β-unsaturated carbonyl compounds, which results in an
oxime, which later on undergo cyclisation.
(1) Fanshawe and Crawley200 prepared isoxazoles (II) from chalcones.
KOH
+
R
O
R'
NH2
OH
.HCl
N
O
R
R'
(II) R, R' = Aryl
(I)
N
O
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(2) Subs t i tu ted i soxazo les  were  prepared by the  reac t ion be tween
hydroxylamine hydrochloride and chalcone dibromides201.
(3) J. F. Hansen and S. A. Strong202 isolated isoxazoles from α,β-unsaturated
ketones and N-bromosuccinamide.
(4) D'Alcontres and G. Ae Gamco203 synthesised isoxazoles from benzonitrile
N-oxide and unsaturated aldehydes.
THERAPEUTIC IMPORTANCE
Isoxazoles have various medicinal applications such as:
(1) Antiinflammatory204-207
(2) Anticonvulsant208,209
(3) Muscle Relaxant210,211
(4) Antipyretic212
(5) Anticholestermic213
(6) Antibacterial214-216
(7) Antidiabetic217
(8) Nematocidal218
(9) Fungicidal219,220
(10) Antiviral221
(11) Herbicidal222, 223
(12) Anthelmintics224
(13) Antileukemic225
(14) Antitumor226
(15) Hypoglycemic227
(16) Analgesic228
Isoxazoles bearing quinazolone moiety were prepared by Maggio et al.229
and tested for their analgesic and antiinflammatory activities. Some of them
had a very low ulcerogenic effect. C. B. Xue and co-worker230 reported the
replacement of the benzamide in XUO57 (potent inhibitor) with an isoxazole
carboxamide resulted in significant improvement in vitro potency. Isoxazoles
Isoxazoles... 94
having pesticidal activity have been synthesised by Masui et al.231 Some
excellent herbicidal results are obtained by Reddy and co-workers232. Nyitrai
et al.233 have reported remarkable anxiolytic and antihypertensive effect of
some new isoxazole derivatives. Mishra and co-workers234 have synthesised
and reported isoxazoles as useful agents for analgesic and antiinflammatory
activities.
Sezer Ozkan et al.235 have prepared 3-(1-phenyl-1,2,3-triazol-4-yl)-
benzisoxazoles (III) and studied their insecticidal activity.
Some isoxazoles are found to possess herbicidal236,237, potential
ant i in f lammator y238,239 ant imicrob ia l ,240,241 es t rogen receptor
modulators242 and inhibitor of p38 MAP kinase activities243. R. Ulrich et al.244
have synthesised some new isoxazole derivatives and reported their adrenergic
antagonist activity.
CONTRIBUTION FROM OUR LABORATORY
A. R. Parikh et al.245 have prepared  some new isoxazoles and documented
them as antimicrobial agent. H. Parekh and co-workers246 have synthesised
new isoxazole derivatives and reported their antitubercular activity.
Xin-Ping Hui et al.247 prepared isoxazole derivatives of type (IV) and tested
their antibacterial activity.
N N
ONO
CH3
R
(IV)
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N
H
O
N
N
N
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W. Chengde and co-workers248 have synthesised isoxazole derivatives and
reported them as endothelin modulators. Herbicidal activity of isoxazole
derivatives have been documented by Q. Chuanmin et al.249 F. Gallemi and
co-workers250 described isoxazoles as antitumor agent. Caroline C. et al.251
prepared isoxazoles of type (V), which have been evaluated for clinical trials for
asthama.
With a view to getting better therapeutic value, it was contemplated to
synthesise isoxazole derivatives incorporating quinoline as parent molecule, to
enhance the overall activity of resulting compounds which have been described
as under.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
3-ARYL-5- (2 ' ,7 ' -DICHLOROQUINOLIN-3 ' -YL) -
ISOXAZOLES
O
N
CH3
S
O
O
NH2
(V)
Isoxazoles... 96
SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-ARYL-5-(2',7'-
DICHLOROQUINOLIN-3'-YL)-ISOXAZOLES.
Isoxazole derivatives are well known for their valid pharmacological
activities. Therefore, it was planned to synthesise some new isoxazoles of type
(VII), bearing 2,7-dichloroquinoline-3-carboxaldehyde nucleus which have been
described as under.
The constitution of the synthesised products have been characterised using
elemental analyses, infra red and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in Part-I, Section-I (D).
NCl Cl
R
O
NCl Cl
N
O
R
R = ArylType (VII)
NH2OH.HCl
CH3COONa
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IR SPECTRAL STUDY OF 3-TOLYL-5- (2 ' ,7 ' -DICHLOROQUINOLIN-3 ' -YL) -
ISOXAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str. 2898 2975-2950 419
C – H. def. 1471 1470-1435 "
Aromatic C– H str. 3082 3080-3030 "
C = C str. 1575 1585-1570 "
C – H. def. 1137 1125-1090 420
808 835-810 "
Quinoline C = N str. 1604 1612-1693 419
moiety C – Cl str. 754 750-700 "
Isoxazole C = C str. 1575 1580-1550 "
C = N str. 1471 1470-1460 "
N – O str. 808 850-810 "
(overlaped)
CH3
N
Cl
Cl
NO
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PMR SPECTRAL STUDY OF 3-(p-ANISYL)-5-(2',7'-DICHLOROQUINOLIN-3'-YL)-
ISOXAZOLE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity J. Value Inference
No. (δ ppm) of Protons in Hz
1. 3.87 3H singlet - Ar-OCH3
2. 6.97-7.00 2H doublet Jih 8.9 Ar-H i,i'
3. 7.34-7.37 2H doublet Jhi 8.81 Ar-H h,h'
4. 7.54-7.58 1H double doublet Jfg 8.79 Ar-Hf
Jfd 2.13
5. 7.88-7.91 1H doublet Jgf 8.68 Ar-Hg
6. 8.04-8.05 1H doublet Jdf 1.93 Ar-Hd
7. 8.98 1H singlet - Ar-Ha
8. 9.0 1H singlet - Ar-HX
CH3
N
Cl
Cl
NO
gf
d
a X
h
i
h'
i'
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EXPANDED AROMATIC REGION
N
Cl
Cl
NO
m/z = 341
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-ARYL-5-(2',7'-
DICHLOROQUINOLIN-3'-YL)-ISOXAZOLES.
[A] Synthesis of 1-Aryl-3-(2',7'-dichloroquinolin-3'-yl)-2-propene-1-ones
See Part (I), Section - 1 (C).
[B] Synthesis of 3-Aryl-5-(2',7'-dichloroquinolin-3'-yl)-isoxazoles
Anhydrous sodium acetate (1.46g, 0.02 mol) dissolved in a minimum
amount of  hot acet ic acid was added to a solut ion of  hydroxylamine
hydrochloride (1.4 g, 0.02 mol) in ethanol (20 ml). This solution was added to
a solution of 1-p-tolyl-3-(2',7'-dichloroquinolin-3'-yl)-2-propene-1-one (3.42 g,
0.01 mol) in ethanol (25 ml). The mixture was heated under reflux on waterbath
for 12 hrs. The product was isolated and recrystallised from ethanol. Yield 64%,
m.p. 174oC. Anal. Calcd. for C19H12N2Cl2O required : C , 64.24%; H, 3.41%;
N, 7.89%;  Found : C, 64.20%; H, 3.44%; N, 7.69%.
TLC Solvent system : Acetone : Benzene : (3 : 7) Visulising Agent : Iodine
Similarly other 3-Aryl-5-(2',7'-dichloroquinolin-3'-yl)-isoxazoles were
prepared. The physical data along with infra red spectral data are recorded in
Table No. 5.
[C] Therapeutic evaluation 3-Aryl-5-(2',7'-dichloroquinolin-3'-yl)-
isoxazoles
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zones of inhibition of the test solutions are recorded Graphical Chart No. 7.
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TABLE NO. 5 : PHYSICAL CONSTANTS OF 3-ARYL-5-(2',7'-DICHLOROQUINOLIN-3'-YL)-ISOXAZOLES
Sr.
No.
1
7a C6H5- C18H10N2Cl2O 341 238 0.682 64 8.21 8.49
7b 3-NH2-C6H4- C18H11N3Cl2O 356 248 0.520 66 11.80 11.55
7c 4-NH2-C6H4- C18H11N3Cl2O 356 210 0.469 68 11.80 12.05
7d 4-Br-C6H4- C18H9N2BrCl2O 420 260 0.652 69 6.67 6.95
7e 4-Cl-C6H4- C18H9N2Cl3O 375.5 186 0.534 70 7.46 7.69
7f 2,6-(OH)2-C6H3- C18H10N2Cl2O3 373 196 0.554 71 7.51 7.57
7g 4-F-C6H4- C18H9N2Cl2FO 359 210 0.480 75 7.80 7.23
7h C4H3O- C16H8N2Cl2O2 331 224 0.587 67 8.46 8.63
7i 2-OH-C6H4- C18H10N2Cl2O2 357 164 0.643 68 7.84 7.59
7j 4-OH-C6H4- C18H10N2Cl2O2 357 216 0.687 69 7.84 7.22
7k 4-OCH3-C6H4- C19H12N2Cl2O2 371 212 0.667 74 7.55 7.55
7l 4-CH3-C6H4- C19H12N2Cl2O 355 174 0.713 64 7.89 7.69
7m 3-NO2-C6H4- C18H9N3Cl2O3 386 252 0.728 62 10.88 10.62
7n 4-NO2-C6H4- C18H9N3Cl2O3 386 128 0.678 69 10.88 10.82
TLC Solvent System : Acetone : Benzene (3 : 7).
Rf
Value
6
Yield
%
7
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GRAPHICAL CHART NO. 7 :  3-ARYL-5-(2’,7’-DICHLOROQUINOLIN-3’-YL)-ISOXAZOLES
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PART - VI
STUDIES ON
IMIDAZOLINONES
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INTRODUCTION
Imidazolinone (I) is a five membered ring containing 2-nitrogen atoms at
the 1- and 3-positions and a carbonyl group at 5- position.
2-Substituted-5-oxoimidazoline was discovered a century back in 1888 by
A. W. Hoffmann252, when he prepared 2-methyl-2-imidazoline (lysidine) by
heating N'-diacetylethylenediamine in a steam of dry hydrogen chloride. A.
Ladenburg253 prepared the same compound by fusing two equivalents of sodium
acetate with one equivalent of ethylenediamine dihydrochloride.
SYNTHETIC ASPECT
Different methods have been documented for the synthesis of imidazolines
in literature254-257. Accordingly, imidazolones can be prepared by the
condensation of substituted azalactones and primary amine under anhydrous
condition. Formation of imidazolones by the aminolysis of oxazalone with amine
has been mentioned in the literature258.
MECHANISM
Azalactone (a) forms amides (b) of α-acylamino acrylic acid by reaction
with different amines. The amide on ring closure reaction is converted into
imidazolinone derivative (c).
N
N
H
O
(I)
Imidazolinones...
The ring closure can be afforded under a variety of conditions, substituted
anilides have been converted into imidazolinone derivatives by the action of
phosphorous oxy-chloride. Scheme (II).
THERAPEUTIC IMPORTANCE
Historically, a wide range of biological activities have been attributed to
imidazolinone derivatives. A number of imidazolinones have resulted in many
potential drugs and are known to possess a broad spectrum of biological activity
such as:
1. Antihistamine259
2. Antiinflammatory260
3. Potent CNS depressant261
4. Antipyretics and analgesic262
5. Anthelmintic263
6. Hypertensive264
7. Local anaesthetic265
8. Monoamine oxidase (MAO) inhibitor266
9. Antiparkinsonian activity267
10. Bactericidal268
11. Anticonvulsant269
105Imidazolinones...
R-NH2
O
N
O
R
X
(a)
NH
O
R
X
O
NH R
(b)
POCl3
N
N
O
R
X
R'
(c)
R' = NH2, Dry C5H5N / Abs. C2H5OH, K2CO3
(II)
Ding M. et al.270 (III) and Pilkington B. et al.271 have reported a new
series of biologically active analogues of 5-oxo-imidazolines.
Yokohama Shuichi et al.272 prepared some new imidazolinone derivatives
having calmodulin inhibitors activity. Jagham Samir et al.273 have documented
imidazolinone derivatives (IV) as histaminergic H3 receptors.
CONTRIBUTION FROM OUR LABORATORY
H. H. Parekh and co-workers have assessed imidazolinones containing
isoniazide274, and s-triazine275 moieties which were demonstrated as potent
antimicrobial agents. A. R. Parikh et al. have synthesised imidazolinones bearing
phthalazine276 and chloramphenicol277 moiety at one position which were
evaluated for their antimicrobial activity.
General structure for above references are as under.
N
N
O
Ph
Ph
Ph NMe
(III)
N
N
O
R
NH2
CH3
O NH2
(IV)
X = NH2 / Aryl - CONH- CH CH
OH CH2OH
; ; N
O
NH
NN
NHHN
;
N
N
N
NH-C2H5HN
;
N
NOH CH3
CH3
(V)
N
N
O
X
Y
R
Z
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Dharti Joshi et al.278 have reported several novel imidazolinones bearing
benzimidazole moiety which were evaluated for their ability to potentiate
antimicrobial activity. Akhil Bhatt et al.279 have reported 4-(4'-arylidene-2'-
phenyl-5'-oxo-imidazoline-1'-yl)-benzophenones which were screened for their
ant imicrobial  act iv i ty.  K.  Par ikh and co-workers280 have synthesised
imidazolinone derivatives and described them as antimicrobial agents. H. H.
Parekh et al.281 have prepared imidazolinone derivatives and reported their
antimicrobial activity.
Stefan A. L. et al.282 have prepared imidazolinones and tested for the
treatment of cyatokine release. Battistina and co-workers283 have demonstrated
some novel imidazolinones to possess insecticidal activity. Anti-HIV activity of
imidazolinone derivatives have been reported by Arthur and co-workers284.
M. Daisuke and co-workers285 prepared 4-oxo-2-thioxoimidazolidine derivatives
(III), which behave as telomerase inhibitors and antitumor agents.
Imidazolinones... 107
;
NH
N
O
CH3
N
N
H
O2N
CONH-
Y = CH3 / C6H5,  Z = H,  R = Aryl
N
Cl
Cl
N
H
N
H
NHNH
S
O
(VI)
Irene and co-workers286 synthesised some new imidazole derivatives
showing antireteroviral activity. Jin-Michel H. et al.287 constructed 2-oxo-
tetrahydro imidazole derivatives (VII) possessing antileishmanial activity.
Biological activity of some new imidazolinone derivatives have been reported
by C. Hamdouchi et al.288
In pursuing the work on the systems incorporating  pharmaceutically active
molecules, 4-imidazolinone derivatives bearing 2,7-dichloroquinoline nucleus
have been synthesised which have been described as under:
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
1N-ARYL-2-PHENYL-4-(2',7'-DICHLOROQUINOLIN-
3'-METHINYL)-5-IMIDAZOLINONES
NN Z
R
Het
O
Z = -CH2,  -C- , - SO2-
O
R = Alkyl, Aryl
;
(VII)
N
CH3
CH3
Het = ;
NO
CH3
S
N
CH3
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1N-ARYL-2-
P H E N Y L - 4 - ( 2 ' , 7 ' - D I C H LO R O Q U I N O L I N - 3 ' - M E T H I N Y L ) - 5 -
IMIDAZOLINONES
Imidazo l inone der iva t ives  possess  var ie t ies  o f  b io log ica l  and
pharmacological properties. Here, we report the synthesis of some new 5-
Imidazolinones of type (VIII). The strategy employed for the synthesis of desired
compounds involved the reaction of 2-phenyl-4-(2',7'-dichloroquinolin-3'-
methinyl)-5-oxazolones with different amines.
The constitution of the synthesised products have been characterised using
elemental analyses, infra red and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in  Part-I, Section-I (D).
NCl Cl
N
N
O
R
NCl Cl
O
N
O
R-NH2
Type (VIII) R = Aryl
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IR SPECTRAL STUDY OF 1N-ANISYL-2-PHENYL-4-(2',7'-DICHLOROQUINOLIN-3'-
METHINYL)-3-IMIDAZOLINONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str. (asym) 2927 2975-2950 419
–CH3 C – H str. (sym) 2829 2880-2860 "
C – H def. (asym) 1446 1470-1435 "
C – H def. (sym) 1375 1385-1370 "
Aromatic C– H str. 3053 3080-3030 "
1591 1585-1570 "
C – H. i.p. def. 1099 1125-1090 420
C – H. o.o.p. def. 823 835-810 "
Quinoline C = N str. 1610 1612-1693 419
moiety C – Cl str. 759 750-700 "
Imidazole C = O str. 1716 1760-1665 "
C – N – C str. 1147 1146-1132 "
Ether C – O – C 1242 1275-1200 418
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PMR SPECTRAL STUDY OF 1N-(p-ANISYL)-2-PHENYL-4-(2',7'-DICHLOROQUINOLIN-
3'-METHINYL)-5-IMIDAZOLINONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity J. Value Inference
No. (δ ppm) of Protons in Hz
1. 3.85 3H singlet - Ar-OCH3
2. 6.93-6.96 2H doublet Jih 8.86 Ar-Hi,i'
3. 7.10-7.13 2H doublet Jhi 8.92 Ar-Hh,h'
4. 7.19-7.23 1H double doublet Jfg 8.72 Ar-Hf
Jfd 1.93
5. 7.34-7.40 3H multiplate - Ar-Hg,j,n
6. 7.46-7.50 1H triplet - Ar-Hi
7. 7.62-7.68 3H multiplate - Ar-Hd,k,m
8. 7.89 1H singlet - Ar-Ha
9. 9.60 1H singlet - Ar-HX
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NCl Cl
N
N
O
O
CH3
g
f
d
a X
h i
h' i'
n
m l
k
j
8a C6H5 1716
8b 2-Cl-C6H4 1716
8c 3-Cl-C6H4 1726
8d 4-Cl-C6H4 1716
8e 2,5-(Cl)2-C6H3 1720
8f 3,4-(Cl)2-C6H3 1710
8g 3-Cl,4-F-C6H3 1714
8h 2-OCH3-C6H4 1714
8i 4-OCH3-C6H4 1716
8j 2-CH3-C6H4 1716
8k 4-CH3-C6H4 1712
8l 2-NO2-C6H4 1718
8m 3-NO2-C6H4 1710
8n 4-NO2-C6H4 1712
Sr.
 No. R
C=O str.
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Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
IR SPECTRAL DATA OF 1N-ARYL-2-PHENYL-4-(2',7'-DICHLOROQUINOLIN-3'-
METHINYL)-5-IMIDAZOLINONES
EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1N-ARYL-2-PHENYL-
4-(2',7'-DICHLOROQUINOLIN-3'-METHINYL)-5-IMIDAZOLINONES
[A] Synthesis of 2-Phenyl-4-(2',7'-dichloroquinolin-3'-methinyl)-5-
oxazolone
This was prepared by the condensation of 2,7-dichloroquinolin-3-
carboxaldehyde with benzoyl glycine in presence of sodium acetate and acetic
anhydride as described by Vogel.289
[B] Synthesis of 1N-Aryl-2-phenyl-4-(2 ' ,7 ' -dichloroquinolin-3 ' -
methinyl)-5-imidazolinones
To a mixture of 2-phenyl-4-(2',7'-dichloroquinolin-3'-methinyl)-5-oxazolone
(3.69 g, 0.01 mol) and ρ-anisidine (1.23 g, 0.01 mol), 20 ml of dry pyridine was
added and contents were refluxed for 9 hrs. Resulting mass was poured onto
crushed ice and neutralised with HCl, filtered and the product was crystallised
from ethanol. Yield 57% m.p. 226oC, Anal. Calcd. for C26H17N3Cl2O2required
: C, 65.83%; H, 3.61%; N, 8.86%; found : C, 65.85%; H, 3.66%; N, 8.60%.
TLC Solvent System : Acetone : Benzene (1.4:8.6) Visulising Agent : Iodine.
Similarly other 1N-Aryl-2-phenyl-4-(2',7'-dichloroquinoline-3'-methiyl)-5-
imidazolinones were prepared. The physical data along with infra red spectral
data are recorded in Table No. 6.
[C] Therapeutic evaluation of 1N-Aryl-2-phenyl-4-(2',7'-dichloro-
quinolin-3-methinyl)-5-imidazolinones
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart
No. 8.
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TABLE NO. 6 : PHYSICAL CONSTANTS OF 1N-ARYL-2-PHENYL-4-(2',7'-DICHLOROQUINOLIN-3'-METHINYL)-5-
IMIDAZOLINONES
Sr.
No.
1
8a C6H5- C25H15N3Cl2O 444 216 0.744 57 9.46 9.24
8b 2-Cl-C6H4- C25H14N3Cl3O 478.5 >300 0.674 56 8.78 8.59
8c 3-Cl-C6H4- C25H14N3Cl3O 478.5 178 0.542 59 8.78 8.25
8d 4-Cl-C6H4- C25H14N3Cl3O 478.5 186 0.771 51 8.78 8.58
8e 2,5-(Cl)2-C6H3- C25H13N3Cl4O 513 220 0.681 53 8.19 8.39
8f 3,4-(Cl)2-C6H3- C25H13N3Cl4O 513 110 0.742 60 8.19 8.44
8g 3-Cl,4-F-C6H3- C25H13N3Cl3FO 496.5 182 0.648 65 8.46 8.29
8h 2-OCH3-C6H4- C26H17N3Cl2O2 474 178 0.694 55 8.86 8.58
8i 4-OCH3-C6H4- C26H17N3Cl2O2 474 226 0.744 57 8.86 8.60
8j 2-CH3-C6H4- C26H17N3Cl2O 458 212 0.548 58 9.17 9.37
8k 4-CH3-C6H4- C26H17N3Cl2O 458 172 0.624 54 9.17 9.40
8l 2-NO2-C6H4- C25H14N4Cl2O3 489 192 0.621 51 11.45 11.23
8m 3-NO2-C6H4- C25H14N4Cl2O3 489 208 0.634 56 11.45 11.67
8n 4-NO2-C6H4- C25H14N4Cl2O3 489 222 0.567 59 11.45 11.18
TLC Solvent System : Acetone : Benzene (1.4 : 8.6).
Rf
Value
6
Yield
%
7
1
1
5
GRAPHICAL CHART NO. 8 :  1N-ARYL-2-PHENYL-4-(2’,7’-DICHLOROQUINOLIN-3’-METHINYL)-5-IMIDAZOLINONES
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PART - VII
STUDIES ON
5-ARYLIDENE-
4-THIAZOLIDINONES
INTRODUCTION
In the family of heterocyclic compounds, thiazolidinones are presumably
important. Thiazolidinones are reported to possess a broad spectrum of biological
activity. 4-Thiazolidinones are derivatives of thiazolidine with a carbonyl group
at 4-position (I). Numerous reports have been appeared in the literature which
highlight their chemistry and use.
The cyclic structure was assigned after recognisation of mercaptoacetic
acid as a primary product of hydrolysis of 3-phenyl-2-phenyl imino-4-
thiazolidinones290.
SYNTHETIC ASPECT
Several methods for the preparation of 4-thiazolidinones are narratted in
literature291-299.
1. R. Nath and K. Shanker300 have prepared 4-thiazolidinone by cyclization
of N-aryl-N'-(2'-pyridyl)-thiocarbamide with chloroacetic acid.
2. I. D. Shah and J. P. Trivedi301 synthesised thiazolidinones from the 4-aryl
thiosemecarbazones by condensing them with chloroacetic acid, α-
bromopropionic acid and α-bromophenyl acetic acid.
Arylidenes...
N
H
S
O
(I)
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NH NH
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ClCH2COOH N
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R, R' = 2- Pyridyl(II)
3. M. Seada and co-workers302 synthesised some new thiazolidinones from
N-thiurea derivatives and chloroacetic acid.
MECHANISM
The reaction proceeds with the tautomerisation of bis-thiourea derivative
which on reaction with chloroacetic acid gives thioether derivative. The later
on cyclodehydration gives 4-thiazolidinones derivative.
THERAPEUTIC IMPORTANCE
Thiazolidinone, being a biologically active molecule, has attracted many
scientist to investigate therapeutic values of thiazolidinone derivatives. 2,3-
Disubstituted thiazolidinones are reported to demonstrate a wide spectrum of
biological activity.
1. Antimicrobial303,304
2. Thrombin inhibitors305
3. Bactericidal306, 307
4. Antidiabetic308
5. Antifungal309,310
6. Antipsychotic311
R'
NH NH
S
N R''
R-CH-COOH
N
S
O
N
N
R'
R
R''
R' = H, Ph, CH3, R'' = Aryl(III)
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7. CNS effect312
8. Antihypertensive313
9. Antiinflammatory314
10. Anthelmintics315
11. Anticonvulsant316
12. Plant Growth Inhibitor317,318
13. H1-histamine antagonists319
14. Antitubercular320
15. Antioxidant321
R. S. Lodhi and co-workers322 have synthesised 4-thiazolidinone
derivatives, which demonstrate antimicrobial, antiinflammatory and analgesic
activities. V. S. Ingle et al.323 have prepared some novel 4-thiazolidinones and
documented as potent antimicrobial agent. Sharma R. C. and co-workers324
have synthesised some new thiazolidin-4-one derivatives (V) as possible
antimicrobial agents.
CONTRIBUTION FROM OUR LABORATORY
4-Thiazol idinones (VI) bearing s- tr iazine325,326, acr idin-9-yl327,
dapson328,329, 6-hydroxypyrimidine330, thymoloxy acetamido331 have been
synthesised by H. H. Parekh et al. and documented as potent antimicrobial
agent.
Parikh et al. have synthesised variety of 4-thiazolidinone derivatives bearing
arsenilic acid332, 2-aryl-1,3,4-thiadiazol333, γ-picolinylamino334, s-triazine335,
benzoylamino acetamido336, sulphonamido-benzoylamino337, substituted
aryl338, substituted quinoline339 moieties and reported as potent antimicrobial
agent.
N
S
O
Ar
(V) Ar = Aryl
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General structure for above references are as under.
A. R. Parikh and co-workers340 have prepared 4-thiazolidinones bearing
quinoline moiety (VIII) and reported their antibacterial activity.
S
N
Z R
X
O
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CH3
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Y  = H, CH3, CH2COOH
Z  = H, CH3, C6H5
R  = Aryl
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X = H, -CH3
R = Aryl
4-Thiazolidinones incorporating benzthiazole nucleus with good antimalarial
activity have been synthesised by Takasu et al.341 Abdel-Megid and co-
worker342 have prepared some new bis-4-thiazolidinone derivatives and
repor ted their antifungal activity. A. Tsutomu and co-workers343 have
synthesised some novel thiazolidine-diones and described them as telomerase
inhibitors. S. G. Kucukguzel et al.344 have reported antimicrobial and antitumor
activity of some novel 4-thiazolidinones (VIII).
S. K. Srivastava et al.345 have described some new 5-arylidene-4-
thiazolidinone derivatives (IX) and documented their antimicrobial, analgesic
and diuretic activities.
In view of the above observations, the synthesis of novel 4-thiazolidinone
derivatives starting from different amines were aimed at investigating therapeutic
importance of these compounds, which has been described as under:
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
2-ARYLIMINO-3N-ARYL-5 - (2 ' , 7 ' -D ICHLORO-
QUINOLIN-3'-METHINYL)-4-THIAZOLIDINONES
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-ARYLIMINO-3N-
A R Y L - 5 - ( 2 ' , 7 ' - D I C H L O R O Q U I N O L I N - 3 ' - M E T H I N Y L ) - 4 -
THIAZOLIDINONES
Thiazolidinone derivatives are known to be among those heterocycles which
find their utility in various fields of life. The significance of this moiety has
increased due to its biocompatibility, which inspired us to synthesis some new
thiazolidinones of type (IX).
The constitution of the synthesised products have been characterised using
elemental analyses, infra red and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in  Part-I, Section-I (D).
NCl Cl
N
SO
N RR
R = ArylType (IX)
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IR SPECTRAL STUDY OF 2-ANISYLIMINO-3N-ANISYL-5-(2' -7 ' -DICHLORO-
QUINOLIN-3'-METHINYL)-4-THIAZOLIDINONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str. 2923 2975-2850 419
C – H def. 1361 1385-1370 "
Aromatic C– H str. 3041 3080-3030 "
C = C str. 1585 1585-1570 "
C – H. def. 1087 1125-1090 420
825 835-810 "
Quinoline C = N str. 1616 1612-1593 419
moiety C – Cl str. 723 750-700 "
Ether C – O – C 1257 1275-1200 "
Thiazolidinone C = O str. 1708 1760-1655 418
C – N str. 1218 1220-1020 "
C – S – C str. 624 700-600 "
N
Cl
Cl
N
S
O
N
O
CH3
O
CH3
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PMR SPECTRAL STUDY OF 2-(o-TOLYL)-IMINO-3N-(o-TOLYL)-5-(2',7'-DICHLORO-
QUINOLIN-3'-METHINYL)-4-THIAZOLIDINONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity J. Value Inference
No. (δ ppm) of Protons in Hz
1. 2.03 3H singlet - Ar-CH3
2. 2.23 3H singlet - Ar-CH3
3. 6.73-6.76 1H doublet Jim 6.62 Ar-Hi
4. 7.06-7.09 1H doublet Jhi 7.31 Ar-Hh
5. 7.17-7.25 3H multiplate - Ar-H f,k,o
6. 7.32-7.48 5H multiplate - Ar-H d,i,j,m,n
7. 7.83-7.86 2H doublet Jef 6.89 Ar-H g,X
8. 8.1 1H singlet - Ar-Ha
NCl Cl
N
SO
N
CH3
CH3
ag
d
f X
o
n
m
l
hi
j
k
124
9a C6H5 1703
9b 4-Cl-C6H4 1707
9c 3,4-(Cl)2-C6H3 1708
9d 4-F-C6H4 1710
9e 2-OCH3-C6H4 1712
9f 4-OCH3-C6H4 1708
9g 2-CH3-C6H4 1703
9h 3-CH3-C6H4 1703
9i 4-CH3-C6H4 1710
9j 2-NO2-C6H4 1714
9k 3-NO2-C6H4 1715
9l 4-NO2-C6H4 1710
Sr.
 No. R C=O str.
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
IR SPECTRAL DATA OF 2-ARYLIMINO-3N-ARYL-5-(2',7'-DICHLOROQUINOLIN-3'-
METHINYL)-4-THIAZOLIDIONES
N
Cl
Cl
N
S
O
N
CH3
CH3
m/z = 504
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-ARYLIMINO-3N-
ARYL-5-(2',7'-DICHLOROQUINOLIN-3'-METHINYL)-4-THIAZOLIDINONES
[A] Synthesis of Bis-thiourea derivatives
A solution of ρ-anisidine (1.23g, 0.01 mol) in methanol and carbon disulfide
was refluxed for 4 hrs., poured into ice water to afford the desired product.
Excess of CS2 was removed by placing the reaction mixture at room temp. for 2
hrs. The crude product was isolated and crystallised in methanol. Yield 80%
m.p. 196oC. Anal Calcd. : C, 63.50%; H, 5.55%; N, 9.72%; Found : C, 62.48%;
H, 5.53%; N, 9.70%.
Similarly other bisthiourea derivatives have been prepared.
[B] Synthesis of 2-Arylimino-3N-aryl-4-thiazolidinone
A solution of 1,3-dianisyl thiourea (2.88 g. 0.01 mol) and chloroacetic acid
in glacial acetic acid (20 ml) was refluxed with fused sodium acetate (1.25 g.
0.015 mol.) for 10 hrs. The reaction mixture was poured into ice water and
glacial acetic acid was neutralised by sodium bicarbonate and crude product
was isolated and crystallised from methanol. Yield 72% m. p. 98oC. Anal Calcd.
C, 62.19%; H, 4.87%; N, 8.53%; Found : C, 62.20%; H, 4.90%; N, 8.51%.
Similarly, other 2-arylimino-3N-aryl-4-thiazolidinones were prepared.
[C] Synthesis of 2-Arylimino-3N-aryl-5-(2',7'-dichloroquinolin-3'-
methinyl)-4-thiazolidinones
A mixture of 1-anisylimino-3-anisyl-5H-4-thaizolidinone (3.28 g., 0.01 mol),
2,7-dichloroquinolin-3-carboxaldehyde (2.26g. 0.01 mol) and fused sodium
acetate (1.25 g. 0.01 mol) were refluxed in glacial acetic acid (25 ml) for 12 hrs.
The reaction mixture was then poured into ice water. The crude mass was isolated
and treated with sodium bisulfide. The solid thus obtained was filtered, washed,
126
dried and crystallised from DMF. Yield 72%, m.p. 284oC. Anal Calcd. for
C27H19N3Cl2O3S: C, 60.45%; H, 3.57%; N, 7.83%; Found : C, 60.43%; H,
3.58%; N, 7.55%.
TLC Solvent System: Acetone : Benzene (4:6), Visulizing Agent : Iodine.
Similarly other 4-thiazolidinone derivatives were prepared. The physical
data along with infra red and spectral data are recorded in Table No. 7.
[D] Therapeutic evaluation of 1-Arylimino-3-aryl-5-(2',7'-dichloro
quinolin-3'-methinyl)-4-thiazolidinones
Antimicrobial testing was carried out as described in Part - I, Section-I
(D). The zones of inhibition of the test solutions are recorded in Graphical
Chart No. 9.
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Molecular
Weight
4
R
2
Molecular
Formula
3
M.P.
oC
5
% of Nitrogen
Calcd.
8
Found
9
TABLE NO. 7 : PHYSICAL CONSTANTS OF 2-ARYLIMINO-3N-ARYL-5-(2',7'-DICHLOROQUINOLIN-3'-METHINYL)-
4-THIAZOLIDINONES
Sr.
No.
1
9a C6H5- C25H15N3Cl2OS 476 272 0.878 59 8.82 8.55
9b 4-Cl-C6H4- C25H13N3Cl4OS 545 264 0.495 63 7.71 7.57
9c 3,4-(Cl)2-C6H3- C25H11N3Cl6OS 614 258 0.485 67 6.84 6.59
9d 4-F-C6H4- C25H13N3Cl2F2OS 512 254 0.675 68 8.20 8.47
9e 2-OCH3-C6H4- C27H19N3Cl2O3S 536 288 0.625 69 7.83 7.60
9f 4-OCH3-C6H4- C27H19N3Cl2O3S 536 284 0.523 72 7.83 7.55
9g 2-CH3-C6H4- C27H19N3Cl2OS 504 294 0.439 70 8.33 8.65
9h 3-CH3-C6H4- C27H19N3Cl2OS 504 242 0.760 66 8.33 8.08
9i 4-CH3-C6H4- C27H19N3Cl2OS 504 234 0.563 69 8.33 8.19
9j 2-NO2-C6H4- C25H13Cl2N5O5S 566 256 0.614 73 12.37 12.59
9k 3-NO2-C6H4- C25H13Cl2N5O5S 566 280 0.512 75 12.37 12.62
9l 4-NO2-C6H4- C25H13Cl2N5O5S 566 276 0.496 72 12.37 12.08
TLC Solvent System : Acetone : Benzene (4 : 6).
Rf
Value
6
Yield
%
7
1
2
8
GRAPHICAL CHART NO. 9 : 2-ARYLIMINO-3N-ARYL-5-(2’,7’-DICHLOROQUINOLIN-3’-METHINYL)-4-
THIAZOLIDINONES
1
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PART - VIII
STUDIES ON
THIAZOLOPYRIMIDINONES
130
INTRODUCTION
Pyrimidinones is very interesting class of heterocyclic compounds having
wide range of applications in medicine and synthetic chemistry. Pyrimidine
derivatives like cytosine (I), urecil (II) and blasticidin (III) occur widely in nature,
have remarkable pharmaceut ical  impor tance bacause of  their  diverse
physiological action. Several analogs of nucleic acids have been used as
compounds that interfere with the synthesis and functioning of nucleic acids,
an example is fluorouracil which has been used in cancer treatment.
Despite considerable localization of -π-electrons at the nitrogen atom of
pyrimidinone, the ring system is still sufficiently aromatic to possess substantial
stability. This has great advantage in the primary synthesis of pyrimidinones.
SYNTHETIC ASPECT
Various methods for the synthesis of pyrimidinones have been cited in the
literature346-349.
1. Rajiv Gupta and co-workers350 improved synthesis of 4-aryl-6-methyl-
1,2,3,4- te t rahydro-pyr imidine-2-one/ th ione-5-carboxaldehyde by
microwave irradiation.
2. Biginelli351 investigated the reaction of an aromatic aldehyde with β-
ketoester and urea or thiourea which yielded pyrimidine derivative (IV).
N
N
H
NH2
O
NH
N
H
O
O N
N O
O
COOH
NH NH2
O
CH3
NH2O
(I) (II) (III)
Pyrimidinones...
MECHANISM
Pyrimidinone derivatives are formed through cycloaddition process. The
reaction proceeds through conjugated addition of urea to the α,β,-unsaturated
system. Here bond formation take place between N-atom of urea and C-atom
of arylidene.
In the first step migration of electron takes place due to the more
electronegativity of O-atom than C-atom. So carbon has positive charge while
nitrogen atom looses proton so it aquires negative charge, with simultaneous
removal of water.
Pyrimidinones...
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THERAPEUTIC IMPORTANCE
The pyrimidinone derivatives have been prooven to be of great importance
in exhibiting and enhancing the biological activities. The important biological
activities shown by the pyrimidinones are as under:
1. Anticonvulsant352
2. Anthelmintics353
3. Cardiovascular354,355
4. Anti HIV356,357
5. Antihypertensive358,359
6. Antiviral360,361
7. Antitumor363,363
8. Antibiotic364
9. Analgesic365
10. Antagonist366-368
11. Antiinflammatory369
Azaryan and co-workers370 synthesised pyrimidine dione as antitumor
agent. Some important drugs of this type have been produced such as zidovudine
(AZT) (V) used in the treatment of AIDS is a close analogue of thymidine. A
very highly useful drug for herpes virus infection is acyclovir (ACV) (VI) because
of its high selectivity.
Anti HIV activity of pyrimidinone molecule has been reported by Watanabe
and Harado371. Paronikyan E.G. and co-workers372 have prepared some new
pyrimidinones of type (VII) and tested their biological activities.
Pyrimidinones...
OOH
N
N
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Antivira l ,  ant i fungal  and insect ic idal  act iv i ty of  pyr imidones was
documented by M. M. Heravi and co-workers373. Sidler and Larson374 have
repor ted pyrimidone derivatives useful as an  α/A adrenergic receptor
antagonists. Antiinflamatory agent bearing parent molecule pyrimidone has been
documented by Modica and co-worker375. Cho et al.376 have prepared
pyrimidinone derivative and reported their antiviral activity. Bantick J. and co-
workers377 synthesised thienopyrimidinediones (VIII) and reported their
antiasthamatic activity.
Baldev Kumar and co-workers378 have prepared a new series of substituted
te t rahydropyr imid ines  and repor ted as  ca lc ium channe l  b lockers .
Antiinflammatory activity of some fused pyrimidinones have been reporeted by
A. E. Galil et al.379 S. Raffaele and co-workers380 have synthesised some new
pyrimidones and documented their anti HIV activity.
Hu Chun et al.381 prepared some new tetrahydropyrimidone derivatives
(IX) and reported them as calcium antagonist. A. Ali et al.382 have synthesised
pyrazolo pyrimidone derivatives (X) and documented their antimicrobial activity.
Pyrimidinones...
(VII)
X N
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NHNH2
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In view of the above observations, it was thought worth while to synthesise
some new pyrimidones bearing 2,7-dichloroquinolin-3-carboxaldehyde nucleus,
which has been described in the following section.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
OF 7- (2 ' ,7 ' -DICHLOROQUINOLIN-3 ' -YL) -2-
ARYLIMINO-3N-ARYLTHIAZOLIDINO[4 ,5 -d ] -
PYRIMIDINE-4,5,6,7-TETRAHYDRO-5-ONES
Pyrimidinones...
(X) R = Aryl
NH
N
H
NHN
O NH R
O
NH
N
H
O
CH3CO2R
(IX)
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 7- (2 ' ,7 ' -
DICHLOROQUINOLIN-3'-YL)-2-ARYLIMINO-3N-ARYLTHIAZOLIDINO
[4,5-d]-PYRIMIDIN-4,5,6,7-TETRAHYDRO-5-ONES
Pyrimidinones are found to have antimicrobial, anti-tumor, CNS depressant,
cardiovascular activities. Keeping this in view, we planned to synthesise some
new pyrimidinones of type (X). The desired pyrimidinones were synthesised
using substituted 4-thiazolidinone with 2,7-dichloroquinolin-3-carboxaldehyde
and urea.
The constitution of the synthesised products have been characterised using
elemental analyses, infra red and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in  Part-I Section-I (D).
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IR SPECTRAL STUDY OF 7-(2'-7'-DICHLOROQUINOLIN-3'-YL)-2-TOLYLIMINO-3N-
TOLYLTHIAZOLIDINO-[4,5-d]-PYRIMIDINE-4,5,6,7-TETRAHYDRO-5-ONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str. 2893 2975-2850 419
C – H def. 1369 1385-1370 "
Aromatic C– H str. 3053 3080-3030 "
C = C str. 1581 1585-1570 "
1473 1520-1480 "
C – H. def. 1053 1070-1000 420
810 835-810 "
Quinoline C = N str. 1608 1612-1593 419
moiety C – Cl str. 752 750-700 "
Thiazolidine C – N str. 1170 1220-1020 418
C – S – C str. 663 700-600 "
Pyrimidinone C = O str. 1687 1690-1630 "
N ClCl
N
H
NH
S
N
N
O
CH3
CH3
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PMR SPECTRAL STUDY OF 7-(2',7'-DICHLOROQUINOLIN-3'-YL)-2-(p-TOLYL)-IMINO-
3N-(p-TOLYL)-THIAZOLIDINO-[4,5-d]-PYRIMIDINE-4,5,6,7-TETRAHYDRO-5-ONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity J. Value Inference
No. (δ ppm) of Protons in Hz
1. 2.35 3H singlet - Ar-CH3
2. 2.41 3H singlet - Ar-CH3
3. 6.84-6.87 2H singlet Jhi 8.13 Ar-H h,h'
4. 7.11-7.17 3H multiplate - Ar-H i,i',f
5. 7.33 4H singlet - Ar-H j,j',k,k'
6. 7.37-7.38 1H doublet Jdf 1.52 Ar-Hd
7. 7.49-7.52 1H doublet Jgf 8.51 Ar-Ha
8. 7.79 1H singlet - Ar-Ha
9. 8.06 1H singlet - Ar-HX
N ClCl
N
H
NH
S
N
N
O
CH3
CH3
j k
j' k'
f
ga
d
X
i'
h'
h
i
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10a C6H5 1687
10b 4-Cl-C6H4 1689
10c 3,4-(Cl)2-C6H3 1690
10d 4-F-C6H4 1691
10e 2-OCH3-C6H4 1689
10f 4-OCH3-C6H4 1689
10g 2-CH3-C6H4 1689
10h 3-CH3-C6H4 1689
10i 4-CH3-C6H4 1687
10j 2-NO2-C6H4 1691
10k 3-NO2-C6H4 1696
10l 4-NO2-C6H4 1680
Sr.
 No. R C=O str.
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
IR SPECTRAL DATA OF 7-(2',7'-DICHLOROQUINOLIN-3'-YL)-2-ARYLIMINO-3N-
ARYL THIAZOLIDINO [4,5,d]-PYRIMIDINE-4,5,6,7-TETRAHYDRO-5-ONES
EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 7- (2 ' ,7 ' -
DICHLOROQUINOLIN-3'-YL)-2-ARYLIMINO-3N-ARYLTHIAZOLIDINO
[4,5-d]-PYRIMIDINE-4,5,6,7-TETRAHYDRO-5-ONES
[A] Synthesis of Bis-thiourea derivatives
See Part - VII, Section - I (A)
[B] Synthesis of 2-Arylimino-3-aryl-5H-4-thiozolidinones
See Part - VII, Section I (B)
[C] Synthesis of 7-(2',7'-Dichloroquinolin-3'-yl)-2-arylimino-3N-aryl
thiazolidino [4,5 d]-pyrimidin-4,5,6,7-tetrahydro-5-ones
A mixture of 2-anisylimino-3-anisyl-5H-4-thiazolidinone (3.28g, 0.01mol),
2,7-dichloroquinolin-3-carboxaldehyde (2.26g, 0.01 mol) and urea (0.56g, 0.01
mol) in methanol was added a few drops of conc. HCl and heated under reflux
for 4 hrs. The product isolated was filtered and crystallised from DMF. Yield
61%,  m.p. 274oC Anal Calcd. for C28H21N5Cl2O3S required : C, 56.57%, H,
3.56%, N, 12.11%; found : C, 56.59%, H, 3.59% N, 12.44%.
TLC Solvent System : Acetone : Benzene (1.2 :8.8), Visulizing Agent : Iodine.
Similarly other pyrimidinones were prepared. The physical data along with
infra red spectral data are reported in Table No. 8.
[D] Therapeutic evaluation of 7-(2',7'-Dichloroquinolin-3'-yl)-2-
arylimino-3N-arylthiozolidino [4,5 d]-pyrimidin-4,5,6,7-tetrahydro-
5-ones
Antimicrobial testing was carried out as described in Part-I, Section-I (D). The
zones of inhibition of the test solutions are recorded in Graphical Chart No. 10.
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TABLE NO. 8 : PHYSICAL CONSTANTS OF 7-(2 ' ,7 ' -DICHLOROQUINOLIN-3 ' -YL) -2-ARYLIMINO-3N-ARYL
THIAZOLIDINO [4,5-d]-PYRIMIDINE-4,5,6,7-TETRAHYDRO-5-ONES
Sr.
No.
1
10a C6H5- C26H17N5Cl2OS 318 176 0.540 68 13.51 13.80
10b 4-Cl-C6H4- C26H15N5Cl4OS 587 208 0.629 60 11.92 11.63
10c 3,4-(Cl)2-C6H3- C26H13N5Cl6OS 656 240 0.551 63 10.67 10.87
10d 4-F-C6H4- C26H15N5Cl2F2OS 554 252 0.721 65 12.63 12.57
10e 2-OCH3-C6H4- C28H21N5Cl2O3S 578 268 0.650 62 12.11 11.88
10f 4-OCH3-C6H4- C28H21N5Cl2O3S 578 274 0.658 61 12.11 12.44
10g 2-CH3-C6H4- C28H21N5Cl2OS 546 256 0.545 60 12.82 12.53
10h 3-CH3-C6H4- C28H21N5Cl2OS 546 260 0.591 65 12.82 12.99
10i 4-CH3-C6H4- C28H21N5Cl2OS 546 262 0.623 69 12.82 12.67
10j 2-NO2-C6H4- C26H15N7Cl2O5S 608 276 0.680 70 16.12 16.33
10k 3-NO2-C6H4- C26H15N7Cl2O5S 608 284 0.730 76 16.12 16.49
10l 4-NO2-C6H4- C26H15N7Cl2O5S 608 242 0.494 72 16.12 15.87
TLC Solvent System : Acetone : Benzene (1.2 : 8.8).
Rf
Value
6
Yield
%
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GRAPHICAL CHART NO. 10 : 7-(2’,7’-DICHLOROQUINOLIN-3’-YL)-2-ARYLIMINO-3N-ARYL-THIAZOLIDINO[4,5-d]
PYRIMIDINE-4,5,6,7-TETRAHYDRO-5-ONES
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PART - IX
STUDIES ON
α-ARYLAMINONITRILES
INTRODUCTION
The nitrile derivatives possess wide range of therapeutic activities such as
antipyretic, analgesic, antiseptic, antimalarial, anticonvulsant and antimicrobial
etc. The first synthesis of nitriles has been reported in 1832 by Wohler and
Liebig383,384 and in 1834 by Pelouce385. Because of their high toxicity, nitriles
are much used in agricultural field. The nitriles are very useful intermediate for
various products such as acrylonitrile for plastics, synthetic rubber, fibers and
phthalonitriles for a dye stuff.
SYNTHETIC ASPECT
A numerous methods for the preparation of nitriles have been reviewed by
David Mowry386. Some current methods are as under:
(i) From halides using NaCN, Al2O3
387
(ii) From alkyl halides using KCN, tetraalkylammonium salt and water in
trace388
(iii) Preparation of metathesis389
(iv) Dehydrating amides using POCl3
390
(v) The pyrolysis of Schiff's base391
(vi) A practical method for the preparation of nitriles from primary amines under
microwave irradiation, has been reported392-394
MECHANISM
The mechanism of nitrile is shown as under.
Arylaminonitriles...
R
O
H
+ CN R C
OH
CN
H+
R C
OH
CN
H
R1-NH2
-H2O
R C
NH
CN
H
R1
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Reaction between CN and aldehyde is a type of nucleophilic substitution
reaction. From the above reaction, it can be seen that a nucleophile (CN) attacks
on the carbonyl carbon of aldehyde and yields cyanohydrin which reacts with
amine to yield nitrile derivatives.
THERAPEUTIC IMPORTANCE
Nitrile shows various biological activities such as
1. Herbicidal and Viricidal395
2. Central nervous stimulants396
3. Antihypotoxic397
4. Antiinflammatory398
5. Antihypertensive399
6. Fungicidal400
7. Antimicrobial401
8. Pesticidal402
9. Antiarrhythymic403
Nitriles with fused pyridine ring were reported as ulcer inhibitor404. The
3'-cyanophenyl alkanoamines were found to be sympathomimetic drugs405
Cardenolide nitriles demonstrated moderate biological activity in rats (Cather
Method)406. The benzylidene derivatives of maleic acid dinitriles showed 98%
effectiveness against tetranychus urticase407. Sabani et al.408 have reported
nitriles as a refrigeration lubricating oil. Nobuyuki and co-workers409 have
described some new nitriles (I) as tumor necrosis factor(TNF) production inhibitors.
(I)
Arylaminonitriles...
:
:
S
N
N
H
N
CN
O
O
O
CH3
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Kobayashi et al.410 have synthesised new derivatives of nitrile. Peterson
I. A. and co-workers411 have studied antiapoptotic activity of some new amino
nitriles. A series of nitriles (II) as novel antioxidants was synthesised by Parmar
V. S. and co-workers412.
Parikh et al.413 prepared acetonitrile derivatives and documented as
bactericidal and fungicidal. Parlo S. and co-workers414 prepared some new
acrylonitrile derivatives (III) and tested their antitubercular activity.
Nosyruva et al.415 have synthesised nitrile derivatives and tested their
antimicrobial activity. Catherine M. and co-workers416 synthesised some new
iminonitriles and reported as thromboxane receptor antagonist. Cyanoguanidine
derivative (IV) has been synthesised and reported as inhibitors of mitochondrial
F, FO, ATPase by A. Karnails et al.417
(II)
N
N
N
NH2
CN
(III)
Arylaminonitriles...
NN
N
H
R1
R2
CN
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The synthesis of nitriles is of current interest owing to their enormous
occurrence in biologically active derivatives. Hence, considerable attention has
been focused on the study of pharmaceutically important nitriles bearing
quinoline moiety as described below.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
α-ARYLAMINO-α-2,7-DICHLOROQUINOLIN-3-YL-
ACETONITRILES
N
N ClCl
NH
N
CN
NH
CF3
F3C
(IV)
Arylaminonitriles... 146
SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF α-ARYLAMINO-α-
2,7-DICHLOROQUINOLIN-3-YL-ACETONITRILES
Nitrile derivatives have received considerable attention in recent years due
to their wide spectrum of biological activities. Led by these considerations, we
have designed some nitriles of type (XI). The technique applied to get the desired
compounds involved the condensat ion of  d i f ferent  amines  wi th  2,7-
dichloroquinolin-3-carboxaldehyde using KCN in presence of glacial acetic acid.
The constitution of the synthesised products have been characterised using
elemental analyses, infra red and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds have been compared
with standard drugs. The details have been cited in  Part-I, Section-I (D).
NCl Cl
CN
NH
R
NCl Cl
CHO
Type (XI) R = Aryl
CH3COOH
R-NH2
KCN
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IR SPECTRAL STUDY OF α-p-ANISYLAMINO-α-2'-7'-DICHLOROQUINOLIN-3-YL-
ACETONITRILE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str. (asym) 2925 2975-2950 419
–CH3 C – H str. (sym) 2880 2880-2850 "
C – H def. (asym) 1442 1475-1450 "
C – H def. (sym) 1340 1385-1370 "
Aromatic C– H str. 3010 3080-3030 "
C = C str. 1562 1585-1570 "
C – H.i.p. def. 1105 1125-1090 420
. 1072 1070-1000 "
C – H. o.o.p def. 823 835-810 "
N – H str. 3305 3400-3200 "
Quinoline C = N str. 1595 1612-1593 419
moiety C – Cl str. 740 750-700 "
Nitrile C = N str. 2202 2260-2200 421
Ether C – O – C str. 1228 1275-1200 "
NCl Cl
CN
NH
O
CH3
PMR SPECTRAL STUDY OF α-p-ANISYLAMINO-α-2,7-DICHLOROQUINOLIN-3-YL-
ACETONITRILE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity J. Value Inference
No. (δ ppm) of Protons in Hz
1. 3.77 3H singlet - Ar-OCH3
2. 5.70 1H singlet - -CHX
3. 6.81-6.87 4H multiplate - Ar-H h,h',i,i'
4. 7.58-7.61 1H double doublet Jfg 8.64 Ar-Hf
Jfd 1.97
5. 7.81-7.84 1H doublet Jgf 8.72 Ar-Hg
6. 8.48-7.54 1H doublet Jdf 1.79 Ar-Hd
7. 8.48 1H singlet - Ar-Ha
NCl Cl
CN
NH
O
CH3
d
f
g a X
h
i
i'
h'
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11a C6H5 2198
11b 2-Cl-C6H4 2196
11c 3-Cl-C6H4 2200
11d 4-Cl-C6H4 2002
11e 2,6-(Cl)2-C6H3 2202
11f 3,4-(Cl)2-C6H3 2210
11g 3-Cl,4-F-C6H4 2203
11h 4-F-C6H4 2200
11i 2-OCH3-C6H4 2202
11j 4-OCH3-C6H4 2202
11k 2-CH3-C6H4 2202
11l 4-CH3-C6H4 2200
11m 2-NO2-C6H4 2201
11n 3-NO2-C6H4 2200
11o 4-NO2-C6H4 2200
Sr.
 No. R
C=N str.
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
IR SPECTRAL DATA OF α -ARYLAMINO-α -2,7-DICHLOROQUINOLIN-3-YL-
ACETONITRILES
EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF α-ARYLAMINO-α-
2,7-DICHLOROQUINOLIN-3-YL-ACETONITRILES
[A] Synthesis of 2,7-Dichloroquinolin-3-carboxaldehydes
See, Part - I, Section - I (B).
[B] Synthesis of α-Arylamino-α-2,7-dichloroquinolin-3-yl-acetonitriles
2,7-Dichloroquinolin-3-carboxaldehyde (2.26 g, 0.01 mol) dissolved in
ethanol (10 ml) was added to potassium cyanide (6.4 g, 0.1 mol) dissolved in
water (8 ml.) followed by glacial acetic acid (12 ml). The contents were then
stirred for 5 mins. to form aldehyde cyanohydrine and kept at 0oC. ρ-Anisidine
(1.23 g, 0.01 mol) in ethanol (10 ml) was added to the reaction mixture, contents
were kept at room temperature for 24 hrs. and poured into ice. The resulting
solid was crystallised from ethanol. Yield 50%, m.p. 126oC. Anal Calcd. for
C18H13N3Cl2O required : C, 60.35%; H, 3.66%; N, 11.73%; found : C, 60.38%;
H, 3.63%; N, 11.71%.
TLC Solvent system : Acetone : Benzene (2.8 : 7.2), Visulizing Agent : Iodine.
Similarly other α-arylamino-α-2,7-dichloroquinolin-3-yl-acetonitriles were
prepared. The physical data along with infra red spectral data are reported in
Table No. 9.
[C] Therapeutic evaluation of α-Arylamino-α-2,7-dichloroquinolin-3-
yl-acetonitriles
Antimicrobial testing was carried out as described in Part - I, Section - I
(D). The zones of inhibition of the test solutions are recorded in Graphical Chart
No. 11.
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TABLE NO. 9 : PHYSICAL CONSTANTS OF α-ARYLAMINO-α-2,7-DICHLOROQUINOLIN-3-YL-ACETONITRILES
Sr.
No.
1
12a C6H5- C17H11N3Cl2 328 110 0.562 58 12.28 12.50
12b 2-Cl-C6H4- C17H10N3Cl3 362.5 162 0.489 64 11.59 11.75
12c 3-Cl-C6H4- C17H10N3Cl3 362.5 120 0.595 63 11.59 11.33
12d 4-Cl-C6H4- C17H10N3Cl3 362.5 176 0.632 61 11.59 11.40
12e 2,6-(Cl)2-C6H3- C17H9N3Cl4 397 138 0.658 66 10.58 10.77
12f 3,4-(Cl)2-C6H3- C17H9N3Cl4 397 140 0.767 72 10.58 10.82
12g 3-Cl,4-F-C6H3- C17H9N3Cl3F 379.5 118 0.684 79 11.07 11.23
12h 4-F-C6H4- C17H10N3Cl2F 346 162 0.639 57 12.14 12.45
12i 2-OCH3-C6H4- C18H13N3Cl2O 358 152 0.527 55 11.73 11.98
12j 4-OCH3-C6H4- C18H13N3Cl2O 358 126 0.510 50 11.73 11.51
12k 2-CH3-C6H4- C18H13N3Cl2 342 162 0.687 45 12.28 12.49
12l 4-CH3-C6H4- C18H13N3Cl2 342 160 0.676 43 12.28 12.53
12m 2-NO2-C6H4- C17H10N4Cl2O2 373 142 0.662 58 15.01 15.24
12n 3-NO2-C6H4- C17H10N4Cl2O2 373 140 0.537 59 15.01 14.68
12o 4-NO2-C6H4- C17H10N4Cl2O2 373 158 0.428 64 15.01 14.79
TLC Solvent System : Acetone : Benzene (2.8 : 7.2).
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GRAPHICAL CHART NO. 11 : α-ARYLAMINO-α-2,7-DICHLOROQUINOLIN-3-YL-ACETONITRILES
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C6H5 C6H5
3-NH2-C6H4 4-NH2-C6H4
4-NH2-C6H4 4-Br-C6H4
4-Br-C6H4 4-Cl-C6
H4
4-Cl-C6H4 4-F-C6H4
2,6-(OH)2-C6H3 C4H3O
4-F-C6H4 2-OH-C6H4
C4H3O 4-OH-C6H4
2-OH-C6H4 4-OCH3-C6H4
4-OH-C6H4 4-CH3-C6H4
4-OCH3-C6H4 3-NO2-C6H4
4-CH3-C6H4 4-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
RR
NCl Cl
R
O
NCl Cl
N
N
CH3O
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4-NO2-C6H4
RR
NCl Cl
N
N
H
R
NCl Cl
N
R
NH2
N
C6H5 C6H5
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4-NO2-C6H4 4-NO2-C6H4
RR
NCl Cl
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NH
N
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ONCl Cl
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C6H5 C6H5
4-Cl-C6H4 4-Cl-C6H4
3,4-(Cl)2-C6H3 3,4-(Cl)2-C6H3
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RC6H5
2-Cl-C6H4
3-Cl-C6H4
4-Cl-C6H4
2,6-(Cl)2-C6H3
3,4-(Cl)2-C6H3
3-Cl, 4-F-C6H3
4-F-C6H4
2-OCH3-C6H4
4-OCH3-C6H4
2-CH3-C6H4
4-CH3-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
NCl Cl
CN
NH
R
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